<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathology of head and neck neoplasms</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathology of head and neck neoplasms</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathology of head and neck neoplasms</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ajit Paintal, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce E Brockstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marvin P Fried, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Brizel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marshall R Posner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H84270687"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The head and neck region includes the upper aerodigestive tract (oral cavity, paranasal sinuses, pharynx, larynx, cervical esophagus  (<a class="graphic graphic_figure graphicRef97306" href="/d/graphic/97306.html" rel="external">figure 1</a>)), thyroid, associated lymph nodes, soft tissues, and bone. The diverse tissues in this anatomic region give rise to a broad spectrum of neoplasms with differing morphologies, molecular alterations, risk factors, and treatment options.</p><p>The most common malignancy of the head and neck is squamous cell carcinoma (SCC) and its variants. Other important primary neoplasms in the head and neck region include tumors of the major and minor salivary glands and mesenchymal lesions of the soft tissues and paranasal sinuses.</p><p>This section will deal primarily with SCC, including its precursors and variants. Selected benign epithelial proliferations are also clinically relevant and are considered here because of their clinical presentation as tumors. The most common forms of salivary gland neoplasia as well as mesenchymal tumors of special clinical significance to this anatomic region are also included. Detailed pathologic discussions of these entities are available in standard references of head and neck pathology [<a href="#rid1">1-4</a>]. The pathology of thyroid cancer is covered separately. (See  <a class="medical medical_review" href="/d/html/7823.html" rel="external">"Atlas of thyroid cytopathology"</a>.)</p><p class="headingAnchor" id="H1063730982"><span class="h1">MANAGEMENT OF PATHOLOGIC SPECIMENS</span><span class="headingEndMark"> — </span>The discussion in this section is focused on squamous cell carcinoma (SCC) since it is the most common malignant tumor affecting the upper aerodigestive tract. Tumors of salivary gland or mesenchymal origin may be similarly approached.</p><p class="headingAnchor" id="H3420192153"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The initial diagnostic workup may utilize biopsy material (either incisional or excisional) or a cytologic specimen (ie, fine needle aspiration [FNA] or cell block).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biopsy </strong>– The conventional procedure for tissue acquisition is biopsy, either incisional or excisional. An excisional biopsy for suspected dysplasia or a potentially resectable tumor is optimal, since the tissue can be properly oriented, and valuable information can be derived from the assessment of tumor infiltration of the underlying connective tissue, as well as the presence of key prognostic factors, such as vascular and perineural invasion. Fixation and tissue processing can then be optimized, both for conventional histology and possible immunohistochemical or molecular studies. </p><p></p><p class="bulletIndent1">Frozen section is not recommended as a stand-alone procedure for diagnostic purposes, as its use will compromise the quality of the submitted tissue. Frozen section may be appropriate to assess the adequacy of a biopsy sample but only if the surgeon is prepared to remove more tumor, not to be frozen, for definitive diagnosis or therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytology </strong>– The primary cytologic modality involved in the evaluation of head and neck lesions is FNA. A thin needle is inserted into the lesion under either palpation or ultrasound guidance. Small tissue fragments as well as individual cells are drawn into the needle by either suction or capillary action. This material is then typically expressed onto glass slides or into liquid medium. Slides may be air-dried for Giemsa or Diff-Quik staining, or quickly immersed in an alcohol-based fixative for Papanicolaou staining. Material may also be expressed into formalin, <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, or other fixatives for a variety of ancillary studies.</p><p></p><p>In the head and neck, FNA is primarily utilized for the evaluation of enlarged cervical lymph nodes, thyroid nodules, and salivary gland masses. Diff-Quik stained slides are often prepared intraprocedurally, allowing for real-time diagnosis and specimen adequacy assessment. However, biopsy is preferred over FNA when more specialized studies are necessary, such as PD-L1 immunohistochemistry (IHC) or human papillomavirus (HPV) testing. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Programmed cell death ligand 1'</a> and  <a class="medical medical_review" href="/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer", section on 'Confirming HPV 16 positivity'</a>.)</p><p class="headingAnchor" id="H1268884020"><span class="h2">Tumor excision and surgical margins</span><span class="headingEndMark"> — </span>Complete excision of the tumor is the goal in most cases of invasive SCC that are managed operatively, and it requires that the surgical margins are free of invasive tumor. Assessment of tumor involvement at the surgical resection margins is an important component of the pathologic examination.</p><p>Given the compact and complex anatomy of the head and neck and the potential distortion of anatomic landmarks that may occur in a resected specimen, communication between the surgeon and the pathologist is essential during and after tumor excision [<a href="#rid5">5</a>]. The real-time geographic relationship of the surgeon and the pathologist varies among institutions. To avoid miscommunication, it may be necessary for the surgeon to accompany the specimen to the gross pathology laboratory to speak directly with the pathologist. Proper orientation, accurate margin designation (usually by inking), and other points of clinical interest are discussed at that time. If indicated, immediate and additional assessments by intraoperative frozen section can then be initiated [<a href="#rid6">6-9</a>].</p><p class="headingAnchor" id="H1567604393"><span class="h3">Surgical margin goals</span><span class="headingEndMark"> — </span>The National Comprehensive Cancer Network (NCCN) has formulated a set of guidelines related to margins of resection, and these are used in the recommendations of the College of American Pathologists (CAP) [<a href="#rid10">10</a>]. These recommendations can be summarized as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete resection of the tumor means the inked specimen margins are negative for in situ and invasive tumor</p><p class="bulletIndent1"><span class="glyph">●</span>Margin adequacy criteria varies by tumor site</p><p class="bulletIndent1"><span class="glyph">●</span>Clear margins are defined as at least 5 mm of clearance from invasive tumor or carcinoma in situ</p><p class="bulletIndent1"><span class="glyph">●</span>Close margins are defined as less than 2 to 5 mm of clearance from invasive tumor or carcinoma in situ, depending on the specific subsite (eg, 2 mm may be regarded as a clear margin for glottic tumors of the larynx)</p><p></p><p>While many studies use 5 mm of clearance as an indicator of an adequate margin, this figure has not been standardized or rigorously validated, and various publications have used distances ranging from 2 to 10 mm as indicators of margin adequacy [<a href="#rid10">10,11</a>]. In addition, the distance between invasive tumor and the excised edge is subject to a long list of poorly controlled potential artifacts, such as specimen shrinkage, method of margin assessment, and plane of tumor sectioning [<a href="#rid12">12</a>]. Generally speaking, most studies have demonstrated a significant improvement in progression-free survival and locoregional recurrence following resection with negative as opposed to positive or "close" margins.</p><p class="headingAnchor" id="H4242420697"><span class="h3">Approach to margin assessment</span><span class="headingEndMark"> — </span>Two approaches to margin assessment are commonly employed [<a href="#rid8">8,13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>"Specimen" margins </strong>– Surgical margins may be identified and designated in the main resection specimen for evaluation via frozen and/or permanent section.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>"Tumor bed" margins </strong>– Surgical margins may be removed from the surgical defect by the surgeon and sent separately for frozen or permanent section evaluation. </p><p></p><p>Following gross assessment, the specimen should be inked and cut perpendicular to the long axis of the tumor. An intraoperative frozen section may be performed on margins that are of interest to the surgeon or that are deemed close on gross inspection by the pathologist. Perpendicular "specimen" margins that include the invasive tumor front as well as the nearest resected edge of the specimen are preferable to en face margins as they allow an accurate measurement of distance between the tumor and margin.</p><p>The use of "tumor bed" margins separately removed from the surgical defect by the surgeon is associated with significantly lower rates of locoregional recurrence-free survival than "specimen" margins in cases where the margins are deemed negative. Furthermore, in cases where the "tumor bed" margin is negative, the distance between the tumor and true margin may be impossible to accurately assess. Despite the advantages to workflow and the preference of some surgeons, the use of "specimen" margins obtained from the main resection specimen should be the preferred manner of margin assessment for both intraoperative assessment as well as permanent section [<a href="#rid14">14,15</a>].</p><p class="headingAnchor" id="H84270693"><span class="h1">SQUAMOUS CELL CARCINOMA PRECURSORS</span><span class="headingEndMark"> — </span>Precursors to squamous cell carcinoma (SCC) include leukoplakia, erythroplakia, and leukoerythroplakia; squamous hyperplasia; squamous dysplasia; and proliferative verrucous leukoplakia. Patients with such mucosal changes potentially suspicious for such precursors should undergo evaluation and diagnostic biopsy.</p><p class="headingAnchor" id="H84270701"><span class="h2">Leukoplakia, erythroplakia, and leukoerythroplakia</span><span class="headingEndMark"> — </span>The clinical terms leukoplakia, erythroplakia, and leukoerythroplakia are oral squamous proliferations manifested as white, red, or speckled mucosal plaques, respectively, and do not denote specific pathologic entities. However, it is helpful to the pathologist to know whether a lesion demonstrates erythroplakic features, since these are more frequently associated with dysplasia or overt malignancy. The diagnosis of dysplasia or invasive carcinoma requires biopsy and microscopic examination.</p><p>Patients with known carcinogenic exposures and such potentially suspicious mucosal changes should undergo a diagnostic biopsy of the suspicious lesion(s). While dentists, oral surgeons, and otolaryngologists are aware of such potentially suspicious mucosal changes, utilizing scrape samples for cytologic study is of unproven efficacy for diagnostic purposes, and no screening procedure obviates the need for diagnostic biopsy [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/3391.html" rel="external">"Chemoprevention and screening in oral dysplasia and squamous cell head and neck cancer", section on 'Screening'</a>.)</p><p class="headingAnchor" id="H84270709"><span class="h2">Squamous hyperplasia</span><span class="headingEndMark"> — </span>The normal oral and pharyngeal mucosa is a nonkeratinized surface that originates from a single layer of relatively small basal cells. As these cells mature and ascend toward the mucosal surface, they become larger due to the acquisition of cytoplasm that contains keratin. Squamous hyperplasia is a reactive phenomenon consisting of a thickened squamous epithelium, and it includes both acanthosis (increased thickness of the spinous layers) and expansion of the basal cell layer (increase in basal/parabasal cells).</p><p>Localized hyperkeratosis, often in the form of a visible plaque, is seen clinically as leukoplakia. Squamous hyperplasia can be due to a variety of causes, ranging from ill-fitting dentures to toxic substances, and frequently results in some accompanying inflammation or granulation tissue. Suprabasilar mitotic figures and individual cell keratinization (dyskeratosis) may be present and make hyperplasia difficult to distinguish from true mild dysplasia.</p><p class="headingAnchor" id="H84270716"><span class="h2">Squamous dysplasia</span><span class="headingEndMark"> — </span>Squamous dysplasia is a premalignant proliferation of squamous epithelium, and it can affect the mucosal surfaces of the upper aerodigestive tract. Squamous dysplasia is accepted as the precursor of SCC in most cancers not related to human papillomavirus (HPV). Squamous dysplasia may be related to a number of etiologic factors including tobacco use, alcohol consumption, and chewing of areca nuts or betel quid. Risk factors for and molecular alterations seen in oral dysplasia and head and neck SCC are discussed separately. (See  <a class="medical medical_review" href="/d/html/3390.html" rel="external">"Epidemiology and risk factors for head and neck cancer", section on 'Risk factors'</a> and  <a class="medical medical_review" href="/d/html/3391.html" rel="external">"Chemoprevention and screening in oral dysplasia and squamous cell head and neck cancer", section on 'Field carcinogenesis and chemoprevention'</a> and  <a class="medical medical_review" href="/d/html/3387.html" rel="external">"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations"</a>.)</p><p>The diagnosis and grading of dysplasia is based on the assessment of a constellation of features related to both nuclear atypia as well as architecture and maturation. Findings commonly used to support a diagnosis of oral squamous dysplasia include nuclear enlargement, irregular nuclear contours, abnormal keratinization (dyskeratosis), irregular cell stratification, and increased mitotic activity.</p><p>The pathologic evaluation of oral epithelial dysplasia remains inexact and is not consistently reproducible. The World Health Organization (WHO) Classification of Head and Neck Tumours endorses a three-tier system for the grading of oral dysplasia (mild, moderate, and severe) [<a href="#rid4">4</a>].</p><p>Similar to the cervical paradigm of HPV-driven squamous dysplasia, oral squamous dysplasia may be graded based upon which third of the epithelium the dysplasia extends to. However, in contrast to the cervical paradigm, grading relies upon a constellation of features. As such, cases often receive a diagnosis of moderate or severe dysplasia based on a high degree of nuclear or architectural atypia, despite only involving the lower third of the epithelium. (See  <a class="medical medical_review" href="/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis"</a>.)</p><p>The WHO architectural and cytologic criteria are meant to improve interobserver agreement in classifying oral epithelial dysplasia [<a href="#rid4">4,17</a>]. Despite this, significant interobserver variability exists in the diagnosis and grading of oral squamous dysplasia. A switch to a two-tiered grading system has been proposed by some authors in order to improve reproducibility [<a href="#rid18">18</a>].</p><p>In contrast to the oral cavity, the WHO Classification of Head and Neck Tumours specifies a two-tier system of nomenclature for squamous dysplasia of the hypopharynx, larynx, and trachea [<a href="#rid4">4</a>]. In this paradigm, dysplastic lesions are regarded as either low-grade dysplasia/squamous intraepithelial lesions or high-grade dysplasia/squamous intraepithelial lesions based on the degree of cytologic and architectural aberration. In this system, cases with the morphologic features of moderate dysplasia are included under the rubric of high-grade dysplasia/intraepithelial lesions based on their relatively high risk of malignant transformation [<a href="#rid19">19</a>]. An optional third category of carcinoma in situ may be employed in cases of high-grade dysplasia/squamous intraepithelial lesions that demonstrate severe full thickness atypia.</p><p>Close clinical follow-up of squamous dysplasia is warranted, since histopathology is limited in its ability to predict malignant transformation. Although dysplasia is regarded as a precancerous condition, precursor lesions in the oral, laryngeal, and pharyngeal mucosa do not necessarily follow a linear progression. Dysplasia can regress, while invasive cancer can occur in the absence of surface dysplasia. Furthermore, dysplasia on a biopsy or resection is not necessarily predictive of subsequent malignancy [<a href="#rid20">20,21</a>].</p><p>Data on the biological behavior of squamous dysplasia in the head and neck are difficult to interpret owing to poor diagnostic reproducibility, inconsistent follow-up, and heterogeneity among different patient populations for underlying risk factors. In A population-based study in the United States included 1888 patients undergoing biopsy for oral leukoplakia, progression rates for cases with no dysplasia, mild dysplasia, moderate dysplasia, and severe dysplasia were 2.2, 11.9, 8.7, and 32.2 percent, respectively [<a href="#rid22">22</a>]. While the presence of any degree of dysplasia was predictive of progression to invasive carcinoma over a five-year follow up, the differences in progression rates among the different grades of dysplasia were not statistical significance in this study. Of note, 39.6 percent of invasive cancers in this series were preceded by biopsies of leukoplakias that lacked dysplasia.</p><p>A meta-analysis of 92 studies demonstrated higher rates of progression to malignancy for moderate/severe dysplasia relative to low-grade dysplasia (HR 2.4) [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H2220859554"><span class="h2">Proliferative verrucous leukoplakia</span><span class="headingEndMark"> — </span>Proliferative verrucous leukoplakia (PVL) is increasingly recognized as an important precursor of SCC in the oral cavity. PVL is best characterized as a clinicopathologic syndrome of field cancerization. The patients are most typically older adult females, and the lesions preferentially involve the gingiva and alveolar mucosa. There is no known association between PVL and alcohol/tobacco use or any infectious agent.</p><p>Early lesions in PVL are nonspecific in appearance and histologically overlap with a number of reactive keratoses. Typical features include voluminous orthokeratosis, acanthosis, an undulating architecture, and sharp demarcation from the adjacent normal epithelium. Lichenoid inflammation may be seen. In progressive lesions, there may be increased bulk of the epithelial proliferation as well as architectural complexity. As the pathologic features of PVL are somewhat nonspecific, diagnosis relies on correlation between the histologic and clinical findings [<a href="#rid24">24</a>].</p><p>Carcinomas arising in the background of PVL are typified by increasing degrees of epithelial bulk, architectural complexity, and endophytic growth. Importantly, cytologic atypia and destructive stromal invasion are not usually seen in either the early lesions or carcinomas that arise in the context of PVL. These findings represent important differences between conventional invasive squamous cell carcinomas and those that arise in association with PVL; they also account for the high degree of interobserver variability observed in the diagnosis of lesions within this spectrum.</p><p>A three-tiered consensus classification system for lesions arising in PVL is proposed [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Corrugated ortho(para)hyperkeratotic lesion, not reactive</p><p class="bulletIndent1"><span class="glyph">●</span>Bulky hyperkeratotic epithelial proliferation, not reactive</p><p class="bulletIndent1"><span class="glyph">●</span>Squamous cell carcinoma</p><p></p><p>While this system has not been widely adopted, it may be useful as a conceptual framework for further research and awareness of this entity.</p><p class="headingAnchor" id="H84270723"><span class="h1">SQUAMOUS CELL CARCINOMA</span><span class="headingEndMark"> — </span>This section discusses pathologic aspects of conventional squamous cell carcinoma (SCC; ie, "not otherwise specified" [NOS]) as well as some variants with special features that may reflect differences in behavior or prognosis. These include verrucous, basaloid, and spindle cell variants of SCC.</p><p class="headingAnchor" id="H84270730"><span class="h2">Invasive squamous cell carcinoma</span></p><p class="headingAnchor" id="H1459302536"><span class="h3">Risk factors</span><span class="headingEndMark"> — </span>While other mechanisms exist, invasive SCC in the head and neck evolves along three major pathways: tumors related to tobacco and alcohol, tumors associated with human papillomavirus (HPV), and tumors related to Epstein-Barr virus. (See  <a class="medical medical_review" href="/d/html/3390.html" rel="external">"Epidemiology and risk factors for head and neck cancer"</a> and  <a class="medical medical_review" href="/d/html/3387.html" rel="external">"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tobacco and alcohol use </strong>– Tobacco- and alcohol-related SCCs are the most common etiologic agents associated with head and neck squamous cell carcinoma. Tumors arising in this background are associated with widespread chromosomal instability, mutations involving <em>TP53</em>, and deletions of <em>CDKN2A </em>[<a href="#rid26">26</a>]<em>.</em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human papillomavirus </strong>– HPV infection (in particular high-risk serotypes such as HPV 16) is responsible for 60 to 80 percent of SCCs arising in the oropharynx (chiefly represented by the lymphoid-rich areas of the base of tongue and tonsil) [<a href="#rid27">27</a>]. </p><p></p><p class="bulletIndent1">HPV has also been identified as the driver of a minority of SCCs arising at a number of other subsites including the larynx, oral cavity, parotid gland, and sinonasal tract. In general, HPV-associated carcinomas tend to occur in younger patients and are associated with sexual activity  (<a class="graphic graphic_table graphicRef129474" href="/d/graphic/129474.html" rel="external">table 1</a>). In the oropharynx, this subset of tumors is associated with early nodal metastases and markedly improved outcomes relative to the degree of nodal involvement. To reflect this, the eighth edition of the American Joint Committee on Cancer (AJCC) staging manual introduced separate staging systems for HPV-associated and HPV-independent tumors of the oropharynx. The treatment of HPV-associated tumors of the head and neck are discussed separately. (See  <a class="medical medical_review" href="/d/html/115014.html" rel="external">"Treatment of human papillomavirus associated oropharyngeal cancer"</a>.)).</p><p></p><p class="bulletIndent1">At other subsites, the prognostic significance of HPV positivity is unclear with conflicting evidence pointing to both improved as well as equivalent outcomes relative to non-HPV-associated tumors [<a href="#rid28">28-30</a>]. (See  <a class="medical medical_review" href="/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1">Morphologically, HPV-driven SCCs of the oropharynx classically show no to minimal keratinization, nested growth, a lack of overlying dysplasia, and absent desmoplasia  (<a class="graphic graphic_picture graphicRef117314" href="/d/graphic/117314.html" rel="external">picture 1</a>). HPV-driven SCCs occurring at other head and neck subsites may have a similar or "warty" morphology in some cases; however, the morphologic spectrum in cases occurring outside of the oropharynx is less well established [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">In clinical practice, the mechanism of HPV-driven carcinogenesis can be exploited by the use of p16 IHC and E6/E7 mRNA in situ hybridization (ISH) (see <a class="local">'Testing for high-risk HPV infection/p16 immunohistochemistry'</a> below). Serotypes other than HPV 16 may have a different biology. Further details on the virology of HPV infection are discussed separately. (See  <a class="medical medical_review" href="/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer"</a> and  <a class="medical medical_review" href="/d/html/8031.html" rel="external">"Virology of human papillomavirus infections and the link to cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein-Barr virus </strong>– Epstein-Barr virus (EBV) is strongly associated with SCC arising in the nasopharynx and may also play a role in primary SCC arising in salivary gland tissue. While associated with almost all cases of nasopharyngeal carcinomas in endemic regions (eg, Southern China, North Africa, Southeast Asia), EBV is also found in the majority of cases of SCC in other regions where nasopharyngeal carcinoma is less common. Given the ubiquity of EBV infection, this suggests that other environmental factors may be important in the pathogenesis of EBV driven SCC. Diet in general and consumption of salted fish in particular have been proposed as playing an important role [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">EBV driven SCC most commonly has an undifferentiated morphology with minimal keratinization and an abundant lymphoid stroma (ie, "lymphoepithelial carcinoma"). The tumor cells display a syncytial growth pattern with indistinct cell borders, large vesicular nuclei, and prominent nucleoli. Desmoplasia is typically not prominent  (<a class="graphic graphic_picture graphicRef73439" href="/d/graphic/73439.html" rel="external">picture 2</a>). Use of RNA ISH for EBV early RNA (EBER) is the standard method for detection of EBV in paraffin embedded tissue.</p><p></p><p class="bulletIndent1">The role of EBV in carcinogenesis is likely related to expression of the LMP1 and LMP2 proteins, which interact with a number of cell-signaling pathways and inhibit apoptosis. While data are limited, EBV driven tumors in the nasopharynx do not appear to have a significantly different prognosis than HPV-driven tumors or non-virus-related tumors in the nasopharynx  (<a class="graphic graphic_picture graphicRef73439" href="/d/graphic/73439.html" rel="external">picture 2</a>) [<a href="#rid32">32,33</a>]. (See  <a class="medical medical_review" href="/d/html/8276.html" rel="external">"Virology of Epstein-Barr virus"</a>.)</p><p></p><p class="headingAnchor" id="H1116176567"><span class="h3">Pathologic features</span><span class="headingEndMark"> — </span>Invasion in SCC is defined as penetration by the neoplastic cells into the underlying connective tissue beneath the basement membrane. This sequence is logically visualized if there is coexistent high-grade surface dysplasia or carcinoma in situ. However, in contrast with other anatomic sites such as the uterine cervix, SCC in the head and neck region may occur without coexistent carcinoma in situ. The histologic appearance of the invasive tumor may be represented by a broad confluent band ("pushing") or by irregular tumor nests, cords, or single cells. Frequently a desmoplastic or fibrous host response accompanies the invasion.</p><p>Keratinization is often deemed the ultimate evidence of squamous cytoplasmic differentiation. Keratinization is typically represented by whorls (pearls) of dense keratin within tumor nests and may be found either focally or more generally in head and neck SCC. By itself, keratinization is not a reliable grading feature, even though in the past grading was based upon resemblance of the tumor to the normal maturation sequence of squamous epithelium. Tenacious tight junctions between cells (visualized as "intercellular bridges") are another important and diagnostically useful feature of squamous differentiation.</p><p>In cases of poorly differentiated SCC where associated squamous dysplasia is not seen and intercellular bridges and frank keratinization are absent, IHC may be used to confirm squamous differentiation. In this context, the transcription factor p63 or its more specific isoform, p40, holds the greatest utility. In some cases, IHC for high molecular weight keratins (CK5/6, 34bE12) may also hold value, although they are less specific.</p><p class="headingAnchor" id="H1186786663"><span class="h3">Prognostic factors</span></p><p class="headingAnchor" id="H1362635896"><span class="h4">Stage</span><span class="headingEndMark"> — </span>Prognostically, the most important factor is the stage of disease, which is principally determined at most sites by tumor size and nodal metastasis. The Tumor, Node, Metastasis (TNM) staging system is widely used, and specific criteria have been developed, depending upon the primary tumor site as follows (see  <a class="medical medical_review" href="/d/html/3393.html" rel="external">"Overview of the diagnosis and staging of head and neck cancer"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral cavity</strong>  (<a class="graphic graphic_table graphicRef110767" href="/d/graphic/110767.html" rel="external">table 2</a>) – (See  <a class="medical medical_review" href="/d/html/3407.html" rel="external">"Treatment of stage I and II (early) head and neck cancer: The oral cavity", section on 'Clinical presentation and diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nasopharynx</strong>  (<a class="graphic graphic_table graphicRef110658" href="/d/graphic/110658.html" rel="external">table 3</a>) – (See  <a class="medical medical_review" href="/d/html/3372.html" rel="external">"Treatment of early and locoregionally advanced nasopharyngeal carcinoma", section on 'Histology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oropharynx</strong>  (<a class="graphic graphic_table graphicRef110640 graphicRef110641" href="/d/graphic/110640.html" rel="external">table 4A-B</a> and <a class="graphic graphic_table graphicRef110659 graphicRef110628" href="/d/graphic/110659.html" rel="external">table 5A-B</a>) – (See  <a class="medical medical_review" href="/d/html/3399.html" rel="external">"Treatment of early (stage I and II) head and neck cancer: The oropharynx", section on 'Staging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypopharynx</strong>  (<a class="graphic graphic_table graphicRef110661 graphicRef110631" href="/d/graphic/110661.html" rel="external">table 6A-B</a>) – (See  <a class="medical medical_review" href="/d/html/3397.html" rel="external">"Treatment of early (stage I and II) head and neck cancer: The hypopharynx", section on 'Anatomy and staging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Larynx</strong>  (<a class="graphic graphic_table graphicRef110769" href="/d/graphic/110769.html" rel="external">table 7</a>) – (See  <a class="medical medical_review" href="/d/html/3388.html" rel="external">"Treatment of early (stage I and II) head and neck cancer: The larynx", section on 'Staging and anatomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nasal cavity and paranasal sinuses</strong>  (<a class="graphic graphic_table graphicRef110768" href="/d/graphic/110768.html" rel="external">table 8</a>) – (See  <a class="medical medical_review" href="/d/html/16861.html" rel="external">"Tumors of the nasal cavity"</a> and  <a class="medical medical_review" href="/d/html/3403.html" rel="external">"Cancer of the nasal vestibule", section on 'Staging'</a> and  <a class="medical medical_review" href="/d/html/3401.html" rel="external">"Paranasal sinus cancer", section on 'Diagnosis and staging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salivary glands</strong>  (<a class="graphic graphic_table graphicRef110617 graphicRef110657" href="/d/graphic/110617.html" rel="external">table 9A-B</a>) – (See  <a class="medical medical_review" href="/d/html/3400.html" rel="external">"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging", section on 'Staging'</a>.)</p><p></p><p class="headingAnchor" id="H2027292917"><span class="h4">The significance of histologic grade</span><span class="headingEndMark"> — </span>Despite its ubiquity, histologic grading of invasive squamous cell carcinoma (SCC) of the head and neck is irreproducible and of limited value. The prognostic value of histologic grading is unclear in regard to its association with survival [<a href="#rid34">34-37</a>]. The criteria used in grading SCC are subjective and usually include mitotic activity, nuclear pleomorphism, and degree of resemblance to normal squamous cells (differentiation). Despite these limitations, histologic grading is mandated by the current College of American Pathologists (CAP) guidelines in resected specimens. The modifiers well  (<a class="graphic graphic_picture graphicRef78595" href="/d/graphic/78595.html" rel="external">picture 3</a>), moderately  (<a class="graphic graphic_picture graphicRef78301" href="/d/graphic/78301.html" rel="external">picture 4</a>), or poorly differentiated carcinoma  (<a class="graphic graphic_picture graphicRef63428" href="/d/graphic/63428.html" rel="external">picture 5</a>) are used.</p><p>Alternative schema for histologic grading that focus on tumor nest size and budding at the invasive front have been proposed. These criteria have been demonstrated to correlate better with outcomes in a small number of series but have not been widely adopted [<a href="#rid38">38,39</a>].</p><p class="headingAnchor" id="H1235586067"><span class="h4">Other prognostic factors</span><span class="headingEndMark"> — </span>Additional prognostic factors can be derived from histopathologic examination and may influence treatment, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor depth of invasion </strong>– Tumor depth of invasion (DOI) is related to the risk of nodal metastases in oral SCC independent of tumor size and has been incorporated into the staging of tumors at this site in the eighth edition of the AJCC Staging Manual [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pattern of invasion </strong>– A prognostic model incorporating pattern of invasion at the invasive front has been shown to be associated with recurrence and overall survival in the oral cavity and potentially at other subsites. In these models, a worst pattern of invasion demonstrating discontinuous groups of small cells or individual cells is associated with poor outcomes [<a href="#rid4">4,7,42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perineural and lymphovascular invasion </strong>– Perineural invasion and invasion of the lymphatic vessels are associated with increased risk of local recurrence or metastasis, respectively [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical margin status </strong>– Local recurrence is associated with margin status as outlined. (See <a class="local">'Tumor excision and surgical margins'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracapsular extension </strong>– Extracapsular extension of tumor from involved lymph nodes into the surrounding fibroconnective tissue is a critical negative prognostic indicator, particularly in non-HPV-associated tumors [<a href="#rid43">43,44</a>]. In most scenarios, the presence of extracapsular extension in a resected specimen, particularly in non-HPV-associated disease, is an indication for adjuvant chemoradiation. As such, this feature has been incorporated into the staging of non-HPV-associated tumors in the eighth edition of the AJCC staging manual. (See  <a class="medical medical_review" href="/d/html/3374.html" rel="external">"Adjuvant radiation therapy or chemoradiation in the management of head and neck cancer", section on 'Approach to adjuvant management'</a>.)</p><p></p><p class="bulletIndent1">To facilitate accurate assessment, grossly involved lymph nodes should be generously sampled for histologic examination and meticulously examined for evidence of extracapsular extension. At minimum, one histologic section per centimeter of tumor should be examined. Stellate tumor deposits within soft tissue without an identifiable lymph node should be regarded as lymph nodes with extensive extracapsular extension for prognostic purposes [<a href="#rid45">45</a>].</p><p></p><p>The diagnosis of extracapsular extension is based on the finding of a tumor breaching the capsule of the lymph node and extending into the surrounding tissue. This assessment may be complicated by biopsy-related artifact and capsular fusion of multiple lymph nodes, among other factors. Despite its seemingly straightforward definition, the assessment of extracapsular extension is notorious for poor reproducibility among observers [<a href="#rid46">46</a>].</p><p>The CAP staging templates include quantification of the extent of extracapsular extension as an optional element. The degree of extracapsular extension may be characterized as macroscopic (greater than 2 mm) or microscopic (less than or equal to 2 mm). While observational data suggest improved outcomes in patients with microscopic relative to macroscopic extracapsular extension, attempts to validate this distinction, as well as the significance of the 2 mm cutpoint, have been mixed [<a href="#rid47">47-49</a>].</p><p class="bulletIndent1">In HPV-associated squamous cell carcinoma of the oropharynx, the prognostic value of extracapsular extension is less well established and may be muted relative to its impact in non-HPV-associated tumors. While initial meta-analyses failed to demonstrate the prognostic significance of extracapsular extension, subsequent studies have established its significance in this subset of patients [<a href="#rid50">50</a>]. As such, while still a significant prognostic factor, extracapsular extension is not formally incorporated into the nodal staging in this subset of patients. A further point of uncertainty relates to the appropriate criteria to define major and minor extracapsular extension in HPV-associated disease. While one study identified extranodal extension of 4 mm as the most relevant cutpoint [<a href="#rid51">51</a>], some clinical trials have used extranodal extension of 1 mm as a cutoff to stratify patients in regard to risk [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/115014.html" rel="external">"Treatment of human papillomavirus associated oropharyngeal cancer", section on 'Dose-reduced adjuvant radiation'</a>.)</p><p></p><p class="headingAnchor" id="H396713569"><span class="h2">Histologic variants of squamous cell carcinoma</span></p><p class="headingAnchor" id="H84270737"><span class="h3">Verrucous carcinoma</span><span class="headingEndMark"> — </span>Verrucous carcinoma accounts for less than 5 percent of cases of SCC; it is an indolent tumor that is most often seen in older adult patients with or without a history of smoking [<a href="#rid53">53</a>]. Despite its name and distinctive morphology, this tumor subtype is unrelated to HPV [<a href="#rid54">54</a>]. Histologically, there is a spectrum of verrucous lesions encountered in the oral cavity, oropharynx, and larynx that makes accurate and reproducible diagnoses difficult.</p><p>Verrucous lesions clinically present as a velvety or warty exophytic mass  (<a class="graphic graphic_picture graphicRef57350" href="/d/graphic/57350.html" rel="external">picture 6</a>). The spectrum of noninvasive mucosal lesions with a verrucoid appearance includes isolated verrucoid hyperplasia  (<a class="graphic graphic_picture graphicRef79465" href="/d/graphic/79465.html" rel="external">picture 7</a>) and lesions associated with proliferative verrucous leukoplakia (PVL). Verrucous lesions are histologically characterized by extensive keratinization, bland cytology, an exophytic growth pattern with thickened club-like projections and broad, bulbous rete pegs. Verrucous carcinoma is distinguished from verrucous hyperplasia based on extension of the lesion into the underlying stroma. </p><p>Verrucous carcinoma by definition does not exhibit conventional destructive invasion or dysplasia. Lesions displaying these features even focally should be characterized as conventional invasive squamous cell carcinomas. As such, the distinction of verrucous carcinoma from a verrucous hyperplasia is difficult and somewhat subjective, particularly in small biopsies. An unequivocal diagnosis of verrucous carcinoma requires the demonstration of extension of the lesion below the epithelial-stromal interface of the adjacent uninvolved mucosa. This critical feature is best assessed in an excisional specimen  (<a class="graphic graphic_picture graphicRef70135" href="/d/graphic/70135.html" rel="external">picture 8</a>).</p><p>When defined by strict criteria, verrucous carcinomas do not metastasize. Although they demonstrate progressive local growth, in some cases into the underlying bone, the prognosis is favorable [<a href="#rid55">55</a>]. Differences in expression of matrix metalloproteinases have been invoked to partially explain the less aggressive behavior of verrucous carcinomas, as compared with conventional SCC [<a href="#rid56">56</a>].</p><p>Complete surgical excision is generally the primary therapy for verrucous carcinomas. Although radiation therapy was historically avoided in verrucous carcinomas because of concerns that radiation may cause conversion of a relatively indolent tumor to a more aggressive poorly differentiated SCC, this concept is no longer considered valid [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H84270744"><span class="h3">Basaloid SCC</span><span class="headingEndMark"> — </span>Basaloid squamous cell carcinomas (SCCs) are typically related to tobacco use and are most commonly localized to the larynx, although they may also occur at other anatomic sites in the head and neck region. Histologically, basaloid SCCs are poorly differentiated and comprised of cells with high nuclear:cytoplasmic ratios and often with brisk mitotic activity and karyorrhexis. Hyaline stroma and necrosis are frequently present, and a trabecular or nested growth pattern with peripheral palisading is typical. Areas of conventional SCC and squamous dysplasia are often admixed. </p><p>Our understanding of basaloid SCC is confounded by the fact that HPV-associated SCCs, typically from the oropharynx, were previously included under this rubric owing to their histologic similarity until basaloid SCC was recognized as a distinct entity. When HPV-associated cases are excluded, and this entity is more strictly defined as proscribed by the fourth edition of the WHO classification of head and neck tumors, basaloid SCCs are found to have a significantly higher mortality and stage at presentation than conventional SCC [<a href="#rid58">58,59</a>].</p><p class="headingAnchor" id="H84270751"><span class="h3">Spindle cell SCC</span><span class="headingEndMark"> — </span>Spindle cell squamous cell carcinomas (SCCs) are rare, poorly differentiated forms of SCC that should not be confused with true sarcomas. Although spindle cell SCC may be found at any site within the head and neck, the most common sites are the larynx and oral cavity. The gross appearance of these tumors varies and can include smooth polypoid nodules, fungating masses, or flat ulcers. Histologically, these tumors morphologically resemble sarcomas frequently with a spindle cell growth pattern and collagenous stroma. Areas of bone and cartilage formation may also be seen  (<a class="graphic graphic_picture graphicRef58508" href="/d/graphic/58508.html" rel="external">picture 9</a>). These areas of mesenchymal differentiation may encompass the entirety of the tumor or be admixed with conventional SCC. In addition to a true sarcoma, the other major element in the differential diagnosis is malignant melanoma. While IHC is useful to classify these tumors correctly, the recognition of foci of conventional SCC (in situ or invasive) is by far the most helpful feature. In difficult cases where morphologic evidence of squamous differentiation is not seen, immunoreactivity for pancytokeratin and markers of squamous differentiation (p63 and p40) may support a diagnosis of spindle cell SCC [<a href="#rid60">60</a>]. In oropharyngeal tumors, the detection of HPV by in situ hybridization (ISH) may also support a diagnosis of SCC.</p><p>The definitive distinction between a true sarcoma and spindle cell SCC may be impossible. In a significant proportion of cases of spindle cell SCC, all immunohistochemical markers of epithelial and squamous differentiation may be negative. [<a href="#rid61">61</a>]. Given the relative rarity of true sarcomas in the head and neck, high-grade sarcomatoid neoplasms of the head and neck are best regarded as spindle cell SCC until proven otherwise, particularly when mucosally based [<a href="#rid4">4</a>]. Even in the context of an irradiated field, a sarcomatoid neoplasm is likely to be a spindle cell SCC [<a href="#rid62">62</a>].</p><p>Spindle cell carcinomas are characterized by high rates of locoregional recurrence [<a href="#rid63">63</a>]. Prognosis has been associated with tumor location, tumor size and stage, DOI, and presence of keratin staining in the spindle cells [<a href="#rid64">64,65</a>]. Data from case series support the role of surgery as primary therapy; some, but not all, have found these tumors to be relatively radioresistant [<a href="#rid64">64,65</a>].</p><p class="headingAnchor" id="H2348743921"><span class="h1">BIOMARKER TESTING IN HEAD AND NECK SQUAMOUS CELL CARCINOMA</span></p><p class="headingAnchor" id="H2530057861"><span class="h2">Testing for high-risk HPV infection/p16 immunohistochemistry</span><span class="headingEndMark"> — </span>While not entirely specific, the detection of high-risk HPV infection in the appropriate clinicopathologic context strongly suggests an oropharyngeal origin in a carcinoma of an unknown primary site in the head and neck. This is particularly the case for tumors of unknown primary sites presenting with lymph node involvement of the upper and mid jugular chain (levels two and three) and with the typical high-risk HPV-associated morphology  (<a class="graphic graphic_picture graphicRef117314" href="/d/graphic/117314.html" rel="external">picture 1</a>). (See <a class="local">'Risk factors'</a> above.).</p><p>P16 is a cell cycle marker whose expression is upregulated in tumor cells with transcriptionally active high-risk HPV owing to the elaboration of the E7 viral oncoprotein and the subsequent destabilization pRB. Owing to its widespread availability and pre-existing use in pathology laboratories in a variety of other contexts, p16 overexpression is commonly used as a surrogate marker for high-risk HPV expression. (See  <a class="medical medical_review" href="/d/html/8031.html" rel="external">"Virology of human papillomavirus infections and the link to cancer"</a> and  <a class="medical medical_review" href="/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer", section on 'Confirming HPV 16 positivity'</a>.)</p><p>Although p16 IHC is a robust indicator of high-risk HPV infection in most cases, a few important caveats exist. First, p16 may be nonspecifically overexpressed in a subset of cases without high-risk HPV infection. Owing to this, the performance characteristics of p16 IHC may differ widely depending on the site of the tumor being tested due to differences in the prevalence of high-risk HPV infection [<a href="#rid66">66</a>]. As such, p16 IHC is typically only of value in primary tumors of the oropharynx or tumors of unknown primary sites involving the upper jugular chain and displaying the typical high-risk HPV associated morphology.</p><p>p16 IHC is assessed in a semiquantitative fashion, typically requiring 70 percent of tumor cells to be reactive to be regarded as positive. While not hard to assess in large, resected specimens, small biopsies and cytology cell blocks with only a small quantity of tumor may be difficult to interpret reliably.</p><p>In addition to p16 IHC, a number of other markers of high-risk HPV infection, including DNA polymerase chain reaction and DNA ISH, have also been utilized. The widespread use of these assays is limited by the technical requirements of these tests. Furthermore, DNA-based assays may produce spurious positive results in that they may detect non-transcriptionally active high-risk HPV (so called "passenger" infection).</p><p>The gold standard and most direct assay for the detection of transcriptionally active high-risk HPV infection is regarded by most authors to be high-risk HPV E6/E7 mRNA ISH. This assay is extremely sensitive as well as specific for the detection of high-risk HPV infection and may be utilized irrespective of site. High-risk HPV mRNA ISH kits are commercially available from several vendors and are compatible with widely available immunohistochemistry platforms. In addition to its specificity relative to p16 IHC, high-risk HPV mRNA ISH is much more reliable in small biopsies and cytology cell blocks [<a href="#rid67">67</a>].</p><p>The College of American Pathologists (CAP) has published guidelines on the topic of HPV testing for head and neck cancer [<a href="#rid68">68</a>]. The recommendations from this group endorse testing for high-risk HPV infection in all oropharyngeal squamous cell carcinomas by p16 IHC. Squamous cell carcinomas of unknown primary site presenting with involvement of a level two or three cervical lymph node should also be tested by p16 IHC. Given a positive result in the latter scenario, a more specific confirmatory test for high-risk HPV infection should be performed in tumors that do not exhibit the typical high-risk HPV-associated morphology. Routine testing of head and neck squamous cell carcinoma outside of these scenarios is not indicated.</p><p>The American Society of Clinical Oncology (ASCO) endorsed the CAP guidelines on this topic with several qualifying statements [<a href="#rid69">69</a>]. Most notably, the ASCO document recommends confirmatory direct testing for high-risk HPV in p16 positive squamous cell carcinomas of unknown primary sites irrespective of nodal station.</p><p>We further offer direct testing for high-risk HPV via mRNA ISH as opposed to p16 IHC in cytology cell blocks and small biopsies, given the difficulties associated with the interpretation of p16 IHC in limited specimens.</p><p class="headingAnchor" id="H1834254988"><span class="h2">PD-L1 immunohistochemistry</span><span class="headingEndMark"> — </span>Treatment regimens incorporating immune checkpoint inhibitors are now commonly employed in the first-line setting for patients with locally advanced, metastatic, or recurrent head and neck squamous cell carcinoma. In this subset of patients, the assessment of PD-L1 expression by IHC is of great importance in determining management. (See  <a class="medical medical_review" href="/d/html/3364.html" rel="external">"Treatment of metastatic and recurrent head and neck cancer"</a>.)</p><p>While multiple scoring systems have been described for use in scoring PD-L1 IHC, the combined positive score (CPS) is typically employed in head and neck squamous cell carcinoma. The method to calculate CPS is discussed separately. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Diagnostic tests'</a>.)</p><p>CPS was employed in clinical trials that led to the approval of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> (a PD-1 inhibitor  (<a class="graphic graphic_picture graphicRef142551" href="/d/graphic/142551.html" rel="external">picture 10</a>)) [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/d/html/3364.html" rel="external">"Treatment of metastatic and recurrent head and neck cancer", section on 'Pembrolizumab with or without platinum and fluorouracil'</a>.)</p><p>Antibody clone selection is also important to PD-L1 IHC scoring in head and neck tumors. While the US Food and Drug Administration approval for <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is linked to the use of the 22C3 antibody clone, utilization of this particular antibody may not be feasible in all laboratories as it requires a specific platform of immunohistochemistry instrumentation. Studies has established that results obtained using an alternative widely available antibody clone, SP263, are comparable to those obtained using 22C3, and as such, these tests may be used interchangeably [<a href="#rid71">71,72</a>]. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Diagnostic tests'</a>.)</p><p>In contrast to high-risk HPV status and genetic driver alterations, PD-L1 expression, as detected by IHC, is labile and often heterogeneous. It is unclear which site of disease or specimen type best correlates with response to immune checkpoint inhibitors in head and neck squamous cell carcinoma. Results obtained from primary tumors as well as metastatic sites of disease may differ [<a href="#rid73">73</a>], and results obtained from small biopsies are often lower than those obtained from resected specimens [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H84270765"><span class="h1">OTHER MUCOSAL EPITHELIAL TUMORS</span></p><p class="headingAnchor" id="H84270772"><span class="h2">Schneiderian papillomas</span><span class="headingEndMark"> — </span>Schneiderian papillomas arise from the mucosa of the nasal cavity and sinuses (Schneiderian epithelium). These lesions may exhibit multifocality. They are divided into three categories:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exophytic papillomas </strong>– Exophytic papillomas arise from the nasal septum and have an everted growth pattern  (<a class="graphic graphic_picture graphicRef61144" href="/d/graphic/61144.html" rel="external">picture 11</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inverted papillomas </strong>– Inverted papillomas arise from the lateral nasal or sinus wall or paranasal sinuses and show an endophytic or mixed exophytic/endophytic growth pattern. The lining of an inverted papilloma consists of multilayered nonkeratinized squamous epithelium with scattered mucous cells and microcysts filled with neutrophils  (<a class="graphic graphic_picture graphicRef72164" href="/d/graphic/72164.html" rel="external">picture 12</a>). (See  <a class="medical medical_review" href="/d/html/3401.html" rel="external">"Paranasal sinus cancer", section on 'Inverted papilloma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oncocytic Schneiderian papillomas </strong>– Oncocytic Schneiderian papillomas (formerly known as cylindrical cell papillomas) arise from the lateral sinus wall or paranasal sinuses and have a stratified lining of bright pink granular columnar cells with microcysts  (<a class="graphic graphic_picture graphicRef77642" href="/d/graphic/77642.html" rel="external">picture 13</a>).</p><p></p><p>Both inverted and oncocytic Schneiderian papillomas carry an increased risk (5 to 10 percent) of subsequent or concurrent carcinoma [<a href="#rid75">75</a>]; thus, wide excision and long-term follow-up are required. Inverted papillomas almost invariably harbor mutually exclusive activating mutations of <em>EGFR</em> or infection by low-risk HPV (lrHPV) serotypes [<a href="#rid76">76</a>]. lrHPV-related inverted papillomas are often associated with an exophytic component and condyloma-like appearance in contrast with <em>EGFR</em> driven lesions. While both groups of inverted papillomas may give rise to invasive squamous cell carcinoma (SCC), this phenomenon is more common in lrHPV driven lesions [<a href="#rid77">77</a>]. By contrast, HPV associated sinonasal SCCs unassociated with Schneiderian papillomas are almost always related to high-risk viral serotypes. (See  <a class="medical medical_review" href="/d/html/8031.html" rel="external">"Virology of human papillomavirus infections and the link to cancer"</a>.)</p><p>Most if not all cases of oncocytic Schneiderian papilloma have been found to be associated with <em>KRAS</em> mutations involving codons 12 and 61. These mutations are also present in associated cases of SCC [<a href="#rid78">78</a>]. </p><p class="headingAnchor" id="H84270779"><span class="h2">Recurrent respiratory papillomatosis</span><span class="headingEndMark"> — </span>Recurrent respiratory papillomatosis (RRP) is a disease associated with HPV infection seen in both adults and children. It is characterized by multiple benign squamous papillomas of the respiratory tract  (<a class="graphic graphic_picture graphicRef63595" href="/d/graphic/63595.html" rel="external">picture 14</a>) and principally involves the larynx. The tracheobronchial tree and the lungs are rarely involved (&lt;1 percent of cases). RRP is also occasionally an incidental finding at autopsy [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/d/html/6303.html" rel="external">"Common causes of hoarseness in children", section on 'Papillomatosis'</a>.)</p><p>RRP typically involves squamociliary junctions, such as tracheostomy stomas (where chronic inflammation induces squamous metaplasia) and iatrogenically induced squamociliary junctions. Morphologically, RRP is a benign condition. However, patients with RRP can experience multiple, multifocal recurrences that require excision. Lower respiratory tract involvement often leads to respiratory obstruction; in this situation, common causes of death include pneumonia, abscesses, parenchymal lung destruction, and respiratory failure [<a href="#rid80">80-83</a>]. </p><p>In children and adolescents, RRP has been associated with vertical transmission of HPV during pregnancy or delivery [<a href="#rid84">84</a>]. However, the rarity of RRP does not correlate with frequency of HPV infection and associated dysplasias in the female genital tract; therefore, HPV infection may be a co-factor, along with other environmental or host factors. In adults, RRP may be related to reactivation of a latent infection or a new mucosal exposure.</p><p>Histologically, RRP consists of benign proliferations of squamous epithelium with HPV associated pathologic changes comparable to those found in the female genital tract. Although the association between dysplasia and possible recurrence or malignant change is controversial, RRP commonly exhibits varying degrees of squamous dysplasia throughout the clinical disease course. HPV 6 and 11, regarded as low-risk genotypes, have been the most commonly documented in RRP. Other high-risk HPV genotypes (eg, 16, 18, 31, 33, 35) are rarely found. (See  <a class="medical medical_review" href="/d/html/8031.html" rel="external">"Virology of human papillomavirus infections and the link to cancer"</a> and  <a class="medical medical_review" href="/d/html/8031.html" rel="external">"Virology of human papillomavirus infections and the link to cancer", section on 'HPV Genotypes and risk of cancer'</a>.)</p><p>Malignant transformation of RRP is rare in either children or adults. SCC is the only malignancy directly associated with RRP, and can potentially affect either the upper or lower respiratory tracts. Potential risk factors for malignant transformation include multiple recurrences, smoking, alcohol consumption, irradiation, immunosuppression, and chemotherapy; these are also associated with the development of SCC. The definitive molecular mechanisms leading to malignancy in RRP are still poorly understood, especially the unexplained association of HPV 6 and 11 in this regard, since these two HPV genotypes are not linked to the development of SCC in other locations. Data suggest that the malignant transformation associated with HPV 11, at least in part, does not involve the disabled retinoblastoma (Rb) signaling pathway and aberrant p53 regulation [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H84270786"><span class="h2">Sinonasal undifferentiated carcinoma</span><span class="headingEndMark"> — </span>Sinonasal undifferentiated carcinoma (SNUC) is a poorly differentiated and rapidly growing malignancy that arises from Schneiderian mucosa. The tumors are composed of sheets, nests, or trabeculae of malignant, pleomorphic cells with round to oval hyperchromatic nuclei, variably prominent nucleoli, and moderate eosinophilic cytoplasm  (<a class="graphic graphic_picture graphicRef72367" href="/d/graphic/72367.html" rel="external">picture 15</a>). Abundant mitotic activity and areas of necrosis are often seen. Minimal if any evidence of squamous, glandular, or neuroendocrine differentiation should be seen by morphology or immunohistochemistry [<a href="#rid86">86,87</a>]. (See  <a class="medical medical_review" href="/d/html/5183.html" rel="external">"Olfactory neuroblastoma (esthesioneuroblastoma)", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/3401.html" rel="external">"Paranasal sinus cancer", section on 'Sinonasal undifferentiated carcinoma'</a>.)</p><p>In addition to excluding poorly differentiated SCC, adenocarcinoma, and neuroendocrine carcinoma, a number of newer entities defined on the basis of genetic alterations should be excluded to establish a diagnosis of SNUC. These include loss of SMARCA4 or SMARCB1, rearrangements involving nuclear protein in testis (NUT), and infection with HPV [<a href="#rid88">88-92</a>]. (See  <a class="medical medical_review" href="/d/html/7623.html" rel="external">"Pathogenesis, clinical features, and diagnosis of Merkel cell (neuroendocrine) carcinoma", section on 'Histopathology'</a> and  <a class="medical medical_review" href="/d/html/4880.html" rel="external">"Squamous cell carcinoma of unknown primary site", section on 'NUT midline carcinoma'</a>.)</p><p>Point mutations involving the <em>IDH1/2</em> genes have been identified in a large proportion of cases of SNUC. In addition to their occurrence in SNUC, similar <em>IDH1/2 </em>genetic alterations have also been identified in small subsets of other high-grade tumor types occurring in the sinonasal tract (high-grade neuroendocrine carcinoma, olfactory neuroblastoma, high-grade adenocarcinoma) [<a href="#rid93">93</a>]. </p><p class="headingAnchor" id="H84270793"><span class="h2">Sinonasal adenocarcinoma</span><span class="headingEndMark"> — </span>Primary head and neck adenocarcinomas can arise from the minor salivary glands or epithelium of the sinonasal tract. Sinonasal adenocarcinomas may resemble common salivary gland tumors, seromucinous tumors, tumors with enteric-type differentiation, or other rare variants [<a href="#rid94">94</a>]. The seromucinous type adenocarcinomas range from low-grade tumors with fusion of glands composed of bland seromucinous cells to those with cystic or tubulopapillary growth patterns  (<a class="graphic graphic_picture graphicRef65748" href="/d/graphic/65748.html" rel="external">picture 16</a>). Tumors within this spectrum often harbor fusions involving kinase proteins (<em>NTRK3</em>, <em>MET</em>, <em>PRKACA</em>) or the <em>BRAF V600E</em> point mutation [<a href="#rid95">95</a>].</p><p>Intestinal-type adenocarcinomas histologically, immunohistochemically, and genetically resemble carcinoma from the lower gastrointestinal tract  (<a class="graphic graphic_picture graphicRef78080" href="/d/graphic/78080.html" rel="external">picture 17</a>) [<a href="#rid96">96-99</a>]. Exposure to wood or leather dust is highly associated with intestinal-type adenocarcinomas arising in the ethmoid sinus, with such exposure reported in more than 90 percent of cases [<a href="#rid100">100</a>]. The clinical behavior of these tumors is more closely related to tumor grade, although intestinal-type adenocarcinomas are reported to be more aggressive than seromucinous-type carcinomas [<a href="#rid101">101,102</a>]. Clinicopathologic correlation is required to exclude a metastasis from the lower gastrointestinal tract. (See  <a class="medical medical_review" href="/d/html/3401.html" rel="external">"Paranasal sinus cancer"</a>.)</p><p class="headingAnchor" id="H84270800"><span class="h1">SALIVARY GLAND TUMORS</span><span class="headingEndMark"> — </span>Salivary gland tumors include a heterogeneous group of lesions. The variable contribution of luminal and abluminal cells, in conjunction with matrix production by the latter, produces a wide range of histologic patterns, even within the same tumor subtype. Most salivary gland tumors are composed of more than one cell type. These can be divided into luminal (acinar and ductal) and abluminal (myoepithelial and basal) types with analogies to the composition of normal salivary glands. A complete classification of benign and malignant salivary gland tumors is available from the World Health Organization (WHO) blue book  (<a class="graphic graphic_table graphicRef116708" href="/d/graphic/116708.html" rel="external">table 10</a>) [<a href="#rid59">59</a>].</p><p>The following section will discuss selected entities of clinicopathologic importance. The diagnosis and treatment of salivary gland tumors are discussed separately. (See  <a class="medical medical_review" href="/d/html/3400.html" rel="external">"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging"</a> and  <a class="medical medical_review" href="/d/html/3377.html" rel="external">"Salivary gland tumors: Treatment of locoregional disease"</a> and  <a class="medical medical_review" href="/d/html/3382.html" rel="external">"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease"</a>.)</p><p>In most cases, fine needle aspiration (FNA) is the diagnostic modality of choice for initial diagnosis and triage of salivary gland tumors. While some common tumor types (eg, Warthin tumor, pleomorphic adenoma) lend themselves to diagnosis via FNA, many others (in particular adenoid cystic carcinoma [ACC] and oncocytic tumors) present a nonspecific morphologic pattern and require resection for accurate diagnosis. The Milan System for Reporting Salivary Gland Cytology is a proposed framework for reporting of salivary gland cytology results that accounts for the diagnostic areas of ambiguity inherent in these specimens [<a href="#rid103">103</a>]. (See <a class="local">'Diagnosis'</a> above.)</p><p class="headingAnchor" id="H84270807"><span class="h2">Benign salivary gland tumors</span><span class="headingEndMark"> — </span>The most common salivary gland tumors are pleomorphic adenoma and Warthin tumor. Both tumors typically have very distinct morphology and as such are readily diagnosed in fine needle aspirates. A cardinal feature of all benign salivary gland tumors is circumscribed growth and the absence of an infiltrative growth pattern.</p><p class="headingAnchor" id="H3307030208"><span class="h3">Warthin tumor</span><span class="headingEndMark"> — </span>Warthin tumor is strongly associated with smoking and occurs almost exclusively in the parotid gland. Warthin tumor is frequently cystic and may often be bilateral. A tripartite histology with areas of cyst formation, bilayered oncocytic epithelium, and lymphoid stroma are present in varying amounts  (<a class="graphic graphic_picture graphicRef61792" href="/d/graphic/61792.html" rel="external">picture 18</a>). In some cases, particularly following FNA, areas of squamous or mucinous metaplasia may be seen and raise the possibility of an oncocytic mucoepidermoid carcinoma (MEC).</p><p class="headingAnchor" id="H84270814"><span class="h3">Pleomorphic adenoma</span><span class="headingEndMark"> — </span>Pleomorphic adenomas arise most frequently in the parotid gland, although these tumors can also be seen in other major and minor salivary glands (especially in the palate). Pleomorphic adenomas are particularly important because malignant tumors (carcinoma ex pleomorphic adenoma) may originate within these lesions. (See <a class="local">'Carcinoma ex pleomorphic adenoma'</a> below.)</p><p>Pleomorphic adenomas contain stromal material as well as groups of epithelial and myoepithelial cells in varying states of organization. Well-formed glands with a myoepithelial layer may coexist with lumenless groups of admixed stromal cells. The myoepithelial cells frequently separate from the epithelial nests and give rise to a chondromyxoid or hyalinized stroma. Thus, the demarcation between epithelial nests and stromal cells may be indistinct, as myoepithelial cells appear to drop off from the epithelial nests  (<a class="graphic graphic_picture graphicRef71010" href="/d/graphic/71010.html" rel="external">picture 19</a>). The different proportions of cell types (luminal and abluminal) and the variable amount and type of stroma give rise to a variety of morphologic appearances and affect the cytologic representation of material obtained on preoperative needle aspirations.</p><p>While by definition lacking infiltrative growth, pleomorphic adenomas may have broad blunt extensions (ie, "pseudopods") that project somewhat beyond the borders of the rest of the lesion. These projections may contribute to recurrence, particularly in cases treated with enucleation.</p><p>The majority of pleomorphic adenoma cases harbor rearrangements involving either <em>HMGA2</em> or<em> PLAG1 </em>[<a href="#rid104">104</a>]<em>.</em></p><p class="headingAnchor" id="H84270828"><span class="h2">Malignant salivary gland tumors</span><span class="headingEndMark"> — </span>The incidence and proportion of malignant tumors of a specific histologic type vary between major and minor salivary glands [<a href="#rid105">105-108</a>]. Furthermore, there are large differences in the relative incidence in different geographic regions. </p><p>Overall, MEC and ACC are the most common histologic types, accounting for 33 and 24 percent of cases, respectively [<a href="#rid105">105</a>]. Key features in identifying malignant potential in any salivary gland tumor include invasion of adjacent tissue, perineural or lymphatic/vascular invasion, and necrosis. In contrast with other anatomic sites, highly aggressive malignant tumors, in particular ACC and myoepithelial carcinoma, may be extremely bland and cytologically monotonous and display minimal mitotic activity.</p><p>For purposes of management, low- and high-grade carcinomas must be accurately distinguished from each other. While MEC is routinely graded in order to drive management, most of the other forms of salivary gland carcinoma have an intrinsic grade [<a href="#rid109">109</a>].</p><p>The pathology of a subset of more common salivary gland malignancies are discussed below [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H84270835"><span class="h3">Mucoepidermoid carcinoma</span><span class="headingEndMark"> — </span>MEC is the most common malignant salivary gland tumor in adults and children [<a href="#rid105">105</a>]. It consists of a mixture of mucin-producing columnar cells, epidermoid (squamous) cells, and polygonal intermediate cells  (<a class="graphic graphic_picture graphicRef60211" href="/d/graphic/60211.html" rel="external">picture 20</a>). Overt keratinization is rare.</p><p>Histologic grade is important in driving the management of this tumor and particularly in determining the need for adjuvant radiation therapy. As a practical matter, low-grade lesions are typically cystic; higher-grade lesions become progressively more solid in growth and more difficult to classify correctly. </p><p>The major competing grading systems (Brandwein, Armed Forces Institute of Pathology [AFIP], and modified Healey) are tabulated and summarized in standard textbooks [<a href="#rid111">111</a>]. The AFIP and Brandwein systems assign points to individual histologic features, which contribute to a final score. Grading of tumors within these schema has the usual problem of interobserver reproducibility. Furthermore, the utility of many of the less contemporary grading systems is questionable as many of the cases used to validate the grading criteria in the past would not be considered MEC by modern criteria.</p><p>A simpler alternative grading system has been proposed by the Memorial Sloan Kettering Cancer Center group, which predominantly evaluates lesions based on the presence of coagulative necrosis and greater than or equal to 4 mitotic figures per 10 high power fields. In this series of 52 confirmed cases of MEC, tumors containing either of these risk factors were classified as high-grade disease, and all patients with such high-grade tumors suffered disease recurrence or died. Recurrence in patients whose tumors lacked these features was limited to a single patient with a positive margin [<a href="#rid112">112</a>].</p><p>A translocation involving (11;19)(q21;p13), which produces a unique fusion product, <em>MECT1-MAML2</em>, occurs in approximately 50 percent of cases of MEC. Although the presence of this translocation was initially regarded as prognostically favorable [<a href="#rid113">113,114</a>], this may not be the case [<a href="#rid115">115</a>], as many cases previously diagnosed as high-grade MEC are now assigned to other histologies. Although testing for a <em>MAML2</em> rearrangement is not indicated for routine diagnosis, it may be useful for detecting mucin poor or oncocytic MEC, particularly when the differential diagnosis includes a benign entity [<a href="#rid116">116</a>]. </p><p class="headingAnchor" id="H84270842"><span class="h3">Adenoid cystic carcinoma</span><span class="headingEndMark"> — </span>ACC was previously considered to be the most common form of malignant minor salivary gland tumor [<a href="#rid105">105</a>]. Many of these cases subsequently have been reclassified as polymorphous adenocarcinoma. ACC arises in both major and minor salivary glands. The tumor is locally aggressive, with recurrences often arising after many years. As such, the five-year survival rate of ACC (77 percent) does not accurately reflect its long-term consequences (45 percent at 15 years) [<a href="#rid117">117</a>].</p><p>Three basic growth patterns are commonly seen: tubular, cribriform  (<a class="graphic graphic_picture graphicRef67445" href="/d/graphic/67445.html" rel="external">picture 21</a>), and solid. These patterns are often mixed, and extensive perineural invasion is seen in almost all resected cases. The biologic aggressiveness of ACC correlates with the presence of a solid component within the tumor [<a href="#rid118">118</a>]. Despite the aggressive behavior of this tumor, the individual cells are monotonous with scant cytoplasm, bland nuclei, and minimal coagulative necrosis and mitotic activity. While ACC may be graded, usually on the basis of its growth pattern, all cases should be considered high grade for the purposes of prognostication and management.</p><p>Despite an often classic appearance, ACC may be difficult to distinguish from other bland monotonous tumors including basal cell adenoma, epithelial myoepithelial-carcinoma, and even cellular pleomorphic adenoma. Similar to these mimics, ACC is comprised of both an epithelial component as well as myoepithelial component, which may be highlighted by immunohistochemistry (IHC) for p63 or its isoform, p40. While IHC for CD117 is often utilized to aid in this distinction, this marker is neither sensitive nor specific for ACC. </p><p><em>MYB-NFIB </em>and <em>MYBL1-NFIB</em> rearrangements can be identified via fluorescence in situ hybridization (FISH) in the majority of cases of ACC and can serve as a useful confirmatory test in difficult cases. While almost all cases of ACC harbor <em>MYB o</em>r <em>MYBL1</em> fusions, a large proportion of cases demonstrate fusion partners other than <em>NFIB </em>[<a href="#rid119">119</a>]<em>. MYB </em>RNA in situ hybridization (ISH), while not widely available, can also be useful in this context and may be more sensitive than FISH [<a href="#rid120">120</a>].</p><p class="headingAnchor" id="H3932376126"><span class="h3">Salivary gland ductal carcinoma</span><span class="headingEndMark"> — </span>Salivary duct carcinoma is a high-grade salivary gland carcinoma, typically occurring in the parotid gland, which bears a biological and morphologic resemblance to triple-negative carcinoma of the breast [<a href="#rid121">121</a>]. (See  <a class="medical medical_review" href="/d/html/783.html" rel="external">"Pathology of breast cancer", section on 'Secretory carcinoma'</a> and  <a class="medical medical_review" href="/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer"</a>.)</p><p>The tumor shows a predominantly solid and nested growth pattern with high-grade cytology and prominent comedonecrosis within tumor nests. The individual cells display marked pleomorphism and have abundant granular eosinophilic cytoplasm, suggestive of apocrine differentiation  (<a class="graphic graphic_picture graphicRef142552" href="/d/graphic/142552.html" rel="external">picture 22</a>).</p><p>IHC stains for mammaglobin, GATA3, and androgen receptor are positive in salivary gland ductal carcinoma consistent with its apocrine mammary phenotype. A significant proportion of cases (20 to 40 percent) will harbor overexpression of human epidermal growth factor receptor 2 (HER2). Identification of this subset is clinically relevant, as such patients with locally advanced or metastatic disease may be candidates for treatments targeting HER2. This topic is discussed separately. (See  <a class="medical medical_review" href="/d/html/3382.html" rel="external">"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease", section on 'HER2 overexpression'</a> and  <a class="medical medical_review" href="/d/html/3382.html" rel="external">"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease", section on 'Androgen receptor positive'</a>.)</p><p class="headingAnchor" id="H84270849"><span class="h3">Polymorphous adenocarcinoma</span><span class="headingEndMark"> — </span>Polymorphous adenocarcinoma is an infiltrative tumor typically originating in minor salivary glands that is composed of bland, uniform cells with multiple growth patterns within the same tumor. Polymorphous adenocarcinoma most commonly occurs in the palate and is almost always low grade.</p><p>These tumors resemble and may be confused with adenoid cystic carcinoma since both are cytologically bland and tend to invade the perineural spaces  (<a class="graphic graphic_picture graphicRef56794" href="/d/graphic/56794.html" rel="external">picture 23</a>); polymorphous adenocarcinoma uncommonly invades bone. Polymorphous adenocarcinoma can be distinguished from its morphologic mimics, primarily ACC and pleomorphic adenoma based on the pattern of p63 and p40 staining. While ACC and pleomorphic adenoma will show scattered p63+/40+ myoepithelial cells throughout the tumor, polymorphous adenocarcinoma will demonstrate a diffuse albeit weaker pattern of p63 reactivity with no staining for p40 [<a href="#rid122">122</a>].</p><p>Cribriform adenocarcinoma of the tongue is regarded by many authors as a variant of polymorphous adenocarcinoma. It is distinguished from polymorphous adenocarcinoma based on the presence of vesicular ("papillary thyroid carcinoma-like") nuclei, a cribriform growth pattern, and predilection for the base of the tongue.</p><p>Genetic alterations involving protein kinase D (<em>PRKD</em>) are characteristic of both polymorphous adenocarcinoma (hotspot mutations) as well as cribriform adenocarcinoma (rearrangements) [<a href="#rid123">123</a>].</p><p class="headingAnchor" id="H1440646695"><span class="h3">Carcinoma ex pleomorphic adenoma</span><span class="headingEndMark"> — </span>Carcinoma ex pleomorphic adenoma is a malignant tumor that may arise from a pre-existing pleomorphic adenoma  (<a class="graphic graphic_picture graphicRef57097" href="/d/graphic/57097.html" rel="external">picture 24</a>). This entity may be present as a sudden growth of a previously stable mass in a salivary gland, usually the parotid gland [<a href="#rid124">124,125</a>]. (See <a class="local">'Pleomorphic adenoma'</a> above.)</p><p>Salivary gland ductal carcinoma and myoepithelial carcinoma are the most common histologies seen in carcinoma ex pleomorphic adenoma [<a href="#rid126">126</a>]. Epithelial-myoepithelial carcinoma and SCC may also occur in this setting. In the case of myoepithelial carcinoma, cases arising in a background of pleomorphic adenoma have a more aggressive disease course than those arising de novo [<a href="#rid127">127</a>]. (See <a class="local">'Salivary gland ductal carcinoma'</a> above.)</p><p>Cases of carcinoma ex pleomorphic adenoma with no or minimal extension into the tissue surrounding the pre-existing pleomorphic adenoma may have a lower incidence of metastatic spread than cases with extensive infiltration into the adjacent tissue. This is in contrast to the previous belief that noninvasive tumors had no metastatic capability. Other important negative prognostic indicators in these cases include myoepithelial carcinoma histology, high mitotic rate, and vascular invasion [<a href="#rid127">127</a>].</p><p>Cases of carcinoma ex pleomorphic adenoma commonly harbor the same recurrent cytogenetic abnormalities involving <em>PLAG1</em> and <em>HMGA2</em> as seen in the preceding pleomorphic adenoma [<a href="#rid128">128</a>].</p><p class="headingAnchor" id="H84270856"><span class="h3">Less common malignant salivary gland tumors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acinic cell carcinoma </strong>– Acinic cell carcinoma is a low-grade primary salivary gland malignancy that occurs almost invariably in the parotid gland. These tumors are comprised of sheets and acini of tumor cells containing abundant coarsely granular cytoplasm. Similar to their normal counterparts, the tumor cells contain abundant zymogen granules. Acinic cell carcinoma exhibits low-grade behavior and is associated with a favorable long-term prognosis [<a href="#rid129">129</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mammary analog secretory carcinoma </strong>– Many cases previously regarded as hypogranular acinic cell carcinoma have now been recognized to harbor recurrent gene fusions involving <em>NTRK </em>and have been designated mammary analog secretory carcinoma (MASC), or secretory carcinoma. These tumors are morphologically and biologically analogous to secretory carcinoma of the breast [<a href="#rid123">123</a>]. (See  <a class="medical medical_review" href="/d/html/3382.html" rel="external">"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease", section on 'Secretory (NTRK gene fusion positive)'</a> and  <a class="medical medical_review" href="/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Squamous cell carcinoma </strong>– Primary SCC may also uncommonly occur in salivary gland tissue. The majority of SCCs that occur in major salivary glands represent metastatic lesions, usually from a cutaneous primary. Less commonly, carcinoma ex pleomorphic adenoma may take the form of SCC. A subset of primary salivary gland SCC may be related to infection with high-risk HPV genotypes [<a href="#rid130">130</a>]. SCC occurring outside of these contexts is extremely rare. (See <a class="local">'Squamous cell carcinoma'</a> above and <a class="local">'Carcinoma ex pleomorphic adenoma'</a> above.)</p><p></p><p class="headingAnchor" id="H84270863"><span class="h1">RARE AND MISCELLANEOUS TUMORS</span></p><p class="headingAnchor" id="H910202689"><span class="h2">Head and neck sarcomas</span><span class="headingEndMark"> — </span>Head and neck sarcomas are rare, accounting for approximately 2 percent of all head and neck malignancies. Head and neck sarcomas are discussed separately. (See  <a class="medical medical_review" href="/d/html/3367.html" rel="external">"Head and neck sarcomas"</a>.)</p><p class="headingAnchor" id="H84270870"><span class="h2">Olfactory neuroblastoma</span><span class="headingEndMark"> — </span>Olfactory neuroblastoma (ONB; esthesioneuroblastoma) is a rare tumor arising from the cribriform plate and paranasal sinuses. The pathology on olfactory neuroblastoma, along with its diagnosis, staging, and treatment, is discussed separately  (<a class="graphic graphic_picture graphicRef50794" href="/d/graphic/50794.html" rel="external">picture 25</a>). (See  <a class="medical medical_review" href="/d/html/5183.html" rel="external">"Olfactory neuroblastoma (esthesioneuroblastoma)"</a>.)</p><p class="headingAnchor" id="H84270877"><span class="h2">Juvenile nasopharyngeal angiofibromas</span><span class="headingEndMark"> — </span>Juvenile nasopharyngeal angiofibromas (JNA) are rare tumors exclusively seen in adolescent males, presenting with epistaxis [<a href="#rid131">131</a>]. The lesion is locally invasive but morphologically deceptively bland, showing thin-walled vessels, devoid of smooth muscle, often exhibiting staghorn shapes, and set in a fibrous to myxoid stroma  (<a class="graphic graphic_picture graphicRef76943" href="/d/graphic/76943.html" rel="external">picture 26</a>). Local involvement of the nasal cavity and paranasal sinuses may be extensive, with occasional invasion of the skull base. Intraoperative bleeding may be marked and potentially life threatening. Preoperative measures to diminish blood loss (eg, tumor embolization) may be clinically useful.</p><p>Some cases appear to be manifestations of the familial adenomatous polyposis syndrome with abnormal nuclear localization of beta-catenin described in stromal cells of the tumor [<a href="#rid131">131,132</a>]. (See  <a class="medical medical_review" href="/d/html/2593.html" rel="external">"Clinical manifestations and diagnosis of familial adenomatous polyposis", section on 'Other manifestations'</a>.)</p><p>A number of growth factors and receptors have been identified in stromal cells of JNA, including vascular endothelial growth factor (VEGF), VEGF receptor 2 (VEGFR2), transforming growth factor beta 1 (TGFbeta1), and insulin-like growth factor 2 (IGF-2) [<a href="#rid131">131,132</a>]. These tumors were previously thought to express androgen receptors but not estrogen receptors (ER). One report has identified strong expression of the more recently described ER isoform, ER-beta [<a href="#rid133">133</a>]. Such receptors may represent potential new treatment targets. </p><p class="headingAnchor" id="H3128795935"><span class="h2">Ameloblastoma</span><span class="headingEndMark"> — </span>Ameloblastomas are rare odontogenic tumors that arise in the jaw. They are typically large, disfiguring, and locally aggressive, although most do not metastasize. Ameloblastomas commonly recur if not adequately resected. These tumors have been associated with the V600E mutation of <em>BRAF</em> and may respond to therapy that targets this pathway [<a href="#rid134">134-136</a>]. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p class="headingAnchor" id="H84270884"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Head and neck neoplasms </strong>– The head and neck region is an anatomically and histologically varied site that gives rise to a broad spectrum of neoplasms with differing morphologies, molecular alterations, risk factors, and treatment options  (<a class="graphic graphic_figure graphicRef97306" href="/d/graphic/97306.html" rel="external">figure 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial diagnostic work-up </strong>– For most head and neck neoplasms, the<strong> </strong>initial diagnostic work-up may utilize biopsy material (either incisional or excisional) or a cytologic specimen (ie, fine needle aspiration [FNA] or cell block). (See <a class="local">'Management of pathologic specimens'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor excision and surgical margins </strong>– For tumors undergoing surgical excision, proper management of the surgical specimen is critical for histopathologic analysis and assessment of surgical margin status. Appropriate communication between the surgeon and pathologist is essential. (See <a class="local">'Tumor excision and surgical margins'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Squamous cell carcinoma precursors </strong>– Precursors to squamous cell carcinoma (SCC) include leukoplakia, erythroplakia, and leukoerythroplakia; squamous hyperplasia; squamous dysplasia; and proliferative verrucous leukoplakia. (See <a class="local">'Squamous cell carcinoma precursors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with known carcinogenic exposures and mucosal changes potentially suspicious for such precursors should undergo evaluation and diagnostic biopsy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with squamous dysplasia, close clinical follow-up is warranted since histopathology is limited in its ability to predict malignant transformation. (See <a class="local">'Squamous dysplasia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Squamous cell carcinoma </strong>– SCC of the various head and neck sites is associated with different clinicopathologic risk factors (eg, tobacco and alcohol use, human papillomavirus [HPV], Epstein-Barr virus [EBV]), morphologies, and management. (See <a class="local">'Squamous cell carcinoma'</a> above and <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prognostic factors </strong>– For patients with SCC, certain histologic risk factors are prognostic and influence treatment, such as staging; tumor depth of invasion (for oral SCC); pattern of invasion; perineural and lymphovascular invasion; surgical margin status; and extracapsular extension. The prognostic value of histologic grading in SCC is unclear. (See <a class="local">'Prognostic factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other mucosal epithelial tumors </strong>– Other mucosal epithelial tumors include Schneiderian papillomas, recurrent respiratory papillomatosis, and sinonasal undifferentiated carcinomas. Schneiderian papillomas, consisting of fungiform papillomas, inverted papillomas, and oncocytic Schneiderian papillomas, most often arise from the ectodermally derived mucosa of the nasal cavity and sinuses (Schneiderian epithelium). (See <a class="local">'Other mucosal epithelial tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salivary gland tumors </strong>– Salivary gland tumors vary histologically and can be benign or malignant. (See <a class="local">'Salivary gland tumors'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Benign tumors </strong>– Common benign tumor histologies include Warthin tumor and pleomorphic adenoma. (See <a class="local">'Benign salivary gland tumors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Malignant tumors </strong>– Common malignant histologies include mucoepidermoid carcinoma; adenoid cystic carcinoma; salivary gland ductal carcinoma; polymorphous adenocarcinoma; and mammary analog secretory carcinoma. (See <a class="local">'Salivary gland tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rare tumors of the head and neck </strong>– Rare tumors of the head and neck region include head and neck sarcomas and olfactory neuroblastoma, among others. (See <a class="local">'Rare and miscellaneous tumors'</a> above.)</p><p></p><p class="headingAnchor" id="H84273206"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges G Kenneth Haines III, MD, and Jerome Taxy, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Biopsy Interpretation of the Upper Aerodigestive Tract and Ear, Stelow EB, Mills SE (Eds), Wolters-Kluwer/Lippincott Williams &amp; Wilkins, Philadelphia 2007.</li><li class="breakAll">Gnepp DR. Diagnostic Surgical Pathology of the Head and Neck, 2nd ed, Saunders Elsevier, Philadelphia 2009.</li><li class="breakAll">Head and Neck Pathology: A Volume in Foundations in Diagnostic Pathology Series, Goldblum JR (Ed), Elsevier Health Sciences, 2006.</li><li class="breakAll">WHO Classification of Tumours: Head and neck tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), IARC, 2022. Vol 9.</li><li><a class="nounderline abstract_t">Devaney KO, Ferlito A, Rinaldo A. The language of surgical pathology--a precis for the head and neck surgeon. Oral Oncol 2004; 40:233.</a></li><li><a class="nounderline abstract_t">Bryne M, Koppang HS, Lilleng R, Kjaerheim A. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 1992; 166:375.</a></li><li><a class="nounderline abstract_t">Brandwein-Gensler M, Teixeira MS, Lewis CM, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 2005; 29:167.</a></li><li><a class="nounderline abstract_t">Black C, Marotti J, Zarovnaya E, Paydarfar J. Critical evaluation of frozen section margins in head and neck cancer resections. Cancer 2006; 107:2792.</a></li><li class="breakAll">Acurio A, Taxy JB. Head and Neck. In: Biopsy interpretation: The frozen section, 2nd ed, Taxy JB, Husain AN, Montag AG (Eds), Wolters Kluwer, Philadelphia 2013. p.211.</li><li><a class="nounderline abstract_t">Williams MD. Determining Adequate Margins in Head and Neck Cancers: Practice and Continued Challenges. Curr Oncol Rep 2016; 18:54.</a></li><li><a class="nounderline abstract_t">Hinni ML, Ferlito A, Brandwein-Gensler MS, et al. Surgical margins in head and neck cancer: a contemporary review. Head Neck 2013; 35:1362.</a></li><li><a class="nounderline abstract_t">Baddour HM Jr, Magliocca KR, Chen AY. The importance of margins in head and neck cancer. J Surg Oncol 2016; 113:248.</a></li><li><a class="nounderline abstract_t">Kubik MW, Sridharan S, Varvares MA, et al. Intraoperative Margin Assessment in Head and Neck Cancer: A Case of Misuse and Abuse? Head Neck Pathol 2020; 14:291.</a></li><li><a class="nounderline abstract_t">Chang AM, Kim SW, Duvvuri U, et al. Early squamous cell carcinoma of the oral tongue: comparing margins obtained from the glossectomy specimen to margins from the tumor bed. Oral Oncol 2013; 49:1077.</a></li><li><a class="nounderline abstract_t">Maxwell JH, Thompson LD, Brandwein-Gensler MS, et al. Early Oral Tongue Squamous Cell Carcinoma: Sampling of Margins From Tumor Bed and Worse Local Control. JAMA Otolaryngol Head Neck Surg 2015; 141:1104.</a></li><li><a class="nounderline abstract_t">Rethman MP, Carpenter W, Cohen EE, et al. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc 2010; 141:509.</a></li><li><a class="nounderline abstract_t">Kujan O, Khattab A, Oliver RJ, et al. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: an attempt to understand the sources of variation. Oral Oncol 2007; 43:224.</a></li><li><a class="nounderline abstract_t">Nankivell P, Williams H, Matthews P, et al. The binary oral dysplasia grading system: validity testing and suggested improvement. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 115:87.</a></li><li><a class="nounderline abstract_t">van Hulst AM, Kroon W, van der Linden ES, et al. Grade of dysplasia and malignant transformation in adults with premalignant laryngeal lesions. Head Neck 2016; 38 Suppl 1:E2284.</a></li><li><a class="nounderline abstract_t">Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Oral premalignant lesions: is a biopsy reliable? J Oral Pathol Med 2007; 36:262.</a></li><li><a class="nounderline abstract_t">Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol 2006; 42:461.</a></li><li><a class="nounderline abstract_t">Brandt BH, Bednarz-Knoll N, Kleinheinz J, et al. RE: Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study. J Natl Cancer Inst 2020; 112:968.</a></li><li><a class="nounderline abstract_t">Iocca O, Sollecito TP, Alawi F, et al. Potentially malignant disorders of the oral cavity and oral dysplasia: A systematic review and meta-analysis of malignant transformation rate by subtype. Head Neck 2020; 42:539.</a></li><li><a class="nounderline abstract_t">Gillenwater AM, Vigneswaran N, Fatani H, et al. Proliferative verrucous leukoplakia: recognition and differentiation from conventional leukoplakia and mimics. Head Neck 2014; 36:1662.</a></li><li><a class="nounderline abstract_t">Thompson LDR, Fitzpatrick SG, Müller S, et al. Proliferative Verrucous Leukoplakia: An Expert Consensus Guideline for Standardized Assessment and Reporting. Head Neck Pathol 2021; 15:572.</a></li><li><a class="nounderline abstract_t">Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517:576.</a></li><li><a class="nounderline abstract_t">Stelow EB, Jo VY, Stoler MH, Mills SE. Human papillomavirus-associated squamous cell carcinoma of the upper aerodigestive tract. Am J Surg Pathol 2010; 34:e15.</a></li><li><a class="nounderline abstract_t">Ramkumar SP, Simpson MC, Adjei Boakye E, et al. High-risk human papillomavirus 16/18 associated with improved survival in sinonasal squamous cell carcinoma. Cancer 2023; 129:1372.</a></li><li><a class="nounderline abstract_t">Fakhry C, Westra WH, Wang SJ, et al. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer 2017; 123:1566.</a></li><li><a class="nounderline abstract_t">Young RJ, Urban D, Angel C, et al. Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma. Br J Cancer 2015; 112:1098.</a></li><li><a class="nounderline abstract_t">Rooper LM, Windon MJ, Hernandez T, et al. HPV-positive Squamous Cell Carcinoma of the Larynx, Oral Cavity, and Hypopharynx: Clinicopathologic Characterization With Recognition of a Novel Warty Variant. Am J Surg Pathol 2020; 44:691.</a></li><li><a class="nounderline abstract_t">Verma N, Patel S, Osborn V, et al. Prognostic significance of human papillomavirus and Epstein-Bar virus in nasopharyngeal carcinoma. Head Neck 2020; 42:2364.</a></li><li><a class="nounderline abstract_t">El-Sharkawy A, Al Zaidan L, Malki A. Epstein-Barr Virus-Associated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis. Front Oncol 2018; 8:265.</a></li><li><a class="nounderline abstract_t">Sethi S, Lu M, Kapke A, et al. Patient and tumor factors at diagnosis in a multi-ethnic primary head and neck squamous cell carcinoma cohort. J Surg Oncol 2009; 99:104.</a></li><li><a class="nounderline abstract_t">Wiernik G, Millard PR, Haybittle JL. The predictive value of histological classification into degrees of differentiation of squamous cell carcinoma of the larynx and hypopharynx compared with the survival of patients. Histopathology 1991; 19:411.</a></li><li><a class="nounderline abstract_t">Chiesa F, Mauri S, Tradati N, et al. Surfing prognostic factors in head and neck cancer at the millennium. Oral Oncol 1999; 35:590.</a></li><li><a class="nounderline abstract_t">Janot F, Klijanienko J, Russo A, et al. Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br J Cancer 1996; 73:531.</a></li><li><a class="nounderline abstract_t">Boxberg M, Bollwein C, Jöhrens K, et al. Novel prognostic histopathological grading system in oral squamous cell carcinoma based on tumour budding and cell nest size shows high interobserver and intraobserver concordance. J Clin Pathol 2019; 72:285.</a></li><li><a class="nounderline abstract_t">Boxberg M, Jesinghaus M, Dorfner C, et al. Tumour budding activity and cell nest size determine patient outcome in oral squamous cell carcinoma: proposal for an adjusted grading system. Histopathology 2017; 70:1125.</a></li><li><a class="nounderline abstract_t">Akhter M, Hossain S, Rahman QB, Molla MR. A study on histological grading of oral squamous cell carcinoma and its co-relationship with regional metastasis. J Oral Maxillofac Pathol 2011; 15:168.</a></li><li><a class="nounderline abstract_t">Tam S, Amit M, Zafereo M, et al. Depth of invasion as a predictor of nodal disease and survival in patients with oral tongue squamous cell carcinoma. Head Neck 2019; 41:177.</a></li><li><a class="nounderline abstract_t">Bravo Vicien ML, Espinach Alvarós J, San José Laporte A, Arderiu Freixa A. [Empyema and splenic abscess]. Med Clin (Barc) 1991; 96:319.</a></li><li><a class="nounderline abstract_t">Maxwell JH, Ferris RL, Gooding W, et al. Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. Cancer 2013; 119:3302.</a></li><li><a class="nounderline abstract_t">Kharytaniuk N, Molony P, Boyle S, et al. Association of Extracapsular Spread With Survival According to Human Papillomavirus Status in Oropharynx Squamous Cell Carcinoma and Carcinoma of Unknown Primary Site. JAMA Otolaryngol Head Neck Surg 2016; 142:683.</a></li><li><a class="nounderline abstract_t">Hasmat S, Mooney C, Gao K, et al. Regional Metastasis in Head and Neck Cutaneous Squamous Cell Carcinoma: An Update on the Significance of Extra-Nodal Extension and Soft Tissue Metastasis. Ann Surg Oncol 2020; 27:2840.</a></li><li><a class="nounderline abstract_t">Lewis JS Jr, Tarabishy Y, Luo J, et al. Inter- and intra-observer variability in the classification of extracapsular extension in p16 positive oropharyngeal squamous cell carcinoma nodal metastases. Oral Oncol 2015; 51:985.</a></li><li><a class="nounderline abstract_t">Arun I, Maity N, Hameed S, et al. Lymph node characteristics and their prognostic significance in oral squamous cell carcinoma. Head Neck 2021; 43:520.</a></li><li><a class="nounderline abstract_t">Wreesmann VB, Katabi N, Palmer FL, et al. Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. Head Neck 2016; 38 Suppl 1:E1192.</a></li><li><a class="nounderline abstract_t">Best DL, Jazayeri HE, McHugh JB, et al. Extent of Extranodal Extension in Oral Cavity Squamous Cell Carcinoma is Not Independently Associated With Overall or Disease-Free Survival at a 2.0-mm Threshold. J Oral Maxillofac Surg 2022; 80:1978.</a></li><li><a class="nounderline abstract_t">Benchetrit L, Torabi SJ, Givi B, et al. Prognostic Significance of Extranodal Extension in HPV-Mediated Oropharyngeal Carcinoma: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg 2021; 164:720.</a></li><li><a class="nounderline abstract_t">Xu B, Saliba M, Alzumaili B, et al. Prognostic impact of extranodal extension (ENE) in surgically managed treatment-naive HPV-positive oropharyngeal squamous cell carcinoma with nodal metastasis. Mod Pathol 2022; 35:1578.</a></li><li><a class="nounderline abstract_t">Ferris RL, Flamand Y, Weinstein GS, et al. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol 2022; 40:138.</a></li><li><a class="nounderline abstract_t">Addante RR, McKenna SJ. Verrucous carcinoma. Oral Maxillofac Surg Clin North Am 2006; 18:513.</a></li><li><a class="nounderline abstract_t">Szentirmay Z, Pólus K, Tamás L, et al. Human papillomavirus in head and neck cancer: molecular biology and clinicopathological correlations. Cancer Metastasis Rev 2005; 24:19.</a></li><li><a class="nounderline abstract_t">Orvidas LJ, Olsen KD, Lewis JE, Suman VJ. Verrucous carcinoma of the larynx: a review of 53 patients. Head Neck 1998; 20:197.</a></li><li><a class="nounderline abstract_t">Impola U, Uitto VJ, Hietanen J, et al. Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol 2004; 202:14.</a></li><li><a class="nounderline abstract_t">Koch BB, Trask DK, Hoffman HT, et al. National survey of head and neck verrucous carcinoma: patterns of presentation, care, and outcome. Cancer 2001; 92:110.</a></li><li><a class="nounderline abstract_t">Fritsch VA, Lentsch EJ. Basaloid squamous cell carcinoma of the larynx: analysis of 145 cases with comparison to conventional squamous cell carcinoma. Head Neck 2014; 36:164.</a></li><li class="breakAll">World Health Organization (WHO) Classification of Tumours Editorial Board. Head and Neck Tumours. In: WHO Classification of Tumours, 4th ed, International Agency for Research on Cancer 2020. https://tumourclassification.iarc.who.int/ (Accessed on May 25, 2021).</li><li><a class="nounderline abstract_t">Bishop JA, Montgomery EA, Westra WH. Use of p40 and p63 immunohistochemistry and human papillomavirus testing as ancillary tools for the recognition of head and neck sarcomatoid carcinoma and its distinction from benign and malignant mesenchymal processes. Am J Surg Pathol 2014; 38:257.</a></li><li><a class="nounderline abstract_t">Heidarian A, Wenig BM. The Most Common Mistake in Laryngeal Pathology and How to Avoid it. Head Neck Pathol 2021; 15:130.</a></li><li><a class="nounderline abstract_t">Lewis JS Jr. Spindle cell lesions--neoplastic or non-neoplastic?: spindle cell carcinoma and other atypical spindle cell lesions of the head and neck. Head Neck Pathol 2008; 2:103.</a></li><li><a class="nounderline abstract_t">Spector ME, Wilson KF, Light E, et al. Clinical and pathologic predictors of recurrence and survival in spindle cell squamous cell carcinoma. Otolaryngol Head Neck Surg 2011; 145:242.</a></li><li><a class="nounderline abstract_t">Minami SB, Shinden S, Yamashita T. Spindle cell carcinoma of the palatine tonsil: report of a diagnostic pitfall and literature review. Am J Otolaryngol 2008; 29:123.</a></li><li><a class="nounderline abstract_t">Olsen KD, Lewis JE, Suman VJ. Spindle cell carcinoma of the larynx and hypopharynx. Otolaryngol Head Neck Surg 1997; 116:47.</a></li><li><a class="nounderline abstract_t">Bishop JA, Ma XJ, Wang H, et al. Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol 2012; 36:1874.</a></li><li><a class="nounderline abstract_t">Wong KS, Krane JF, Jo VY. Heterogeneity of p16 immunohistochemistry and increased sensitivity of RNA in situ hybridization in cytology specimens of HPV-related head and neck squamous cell carcinoma. Cancer Cytopathol 2019; 127:632.</a></li><li><a class="nounderline abstract_t">Lewis JS Jr, Beadle B, Bishop JA, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med 2018; 142:559.</a></li><li><a class="nounderline abstract_t">Fakhry C, Lacchetti C, Rooper LM, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. J Clin Oncol 2018; 36:3152.</a></li><li><a class="nounderline abstract_t">Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394:1915.</a></li><li><a class="nounderline abstract_t">Cerbelli B, Girolami I, Eccher A, et al. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study. Histopathology 2022; 80:397.</a></li><li><a class="nounderline abstract_t">Hodgson A, Slodkowska E, Jungbluth A, et al. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma. Am J Surg Pathol 2018; 42:1059.</a></li><li><a class="nounderline abstract_t">Kaur A, Kuchta K, Watkin W, et al. Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma. Arch Pathol Lab Med 2023; 147:442.</a></li><li><a class="nounderline abstract_t">Liu Z, Williams M, Stewart J, et al. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma. Cancer Cytopathol 2022; 130:110.</a></li><li><a class="nounderline abstract_t">Lawson W, Patel ZM. The evolution of management for inverted papilloma: an analysis of 200 cases. Otolaryngol Head Neck Surg 2009; 140:330.</a></li><li><a class="nounderline abstract_t">Maisch S, Mueller SK, Traxdorf M, et al. Sinonasal papillomas: A single centre experience on 137 cases with emphasis on malignant transformation and EGFR/KRAS status in "carcinoma ex papilloma". Ann Diagn Pathol 2020; 46:151504.</a></li><li><a class="nounderline abstract_t">Mehrad M, Stelow EB, Bishop JA, et al. Transcriptionally Active HPV and Targetable EGFR Mutations in Sinonasal Inverted Papilloma: An Association Between Low-risk HPV, Condylomatous Morphology, and Cancer Risk? Am J Surg Pathol 2020; 44:340.</a></li><li><a class="nounderline abstract_t">Udager AM, McHugh JB, Betz BL, et al. Activating KRAS mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma. J Pathol 2016; 239:394.</a></li><li><a class="nounderline abstract_t">Can NT, Tretiakova MS, Taxy JB. Natural History and Malignant Transformation in Recurrent Respiratory Papillomatosis: Human Papillomavirus (HPV), Dysplasia and an Autopsy Review. Fetal Pediatr Pathol 2015; 34:80.</a></li><li><a class="nounderline abstract_t">Campisi P, Hawkes M, Simpson K, Canadian Juvenile Onset Recurrent Respiratory Papillomatosis Working Group. The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database. Laryngoscope 2010; 120:1233.</a></li><li><a class="nounderline abstract_t">Lee JH, Smith RJ. Recurrent respiratory papillomatosis: pathogenesis to treatment. Curr Opin Otolaryngol Head Neck Surg 2005; 13:354.</a></li><li><a class="nounderline abstract_t">Ruan SY, Chen KY, Yang PC. Recurrent respiratory papillomatosis with pulmonary involvement: a case report and review of the literature. Respirology 2009; 14:137.</a></li><li><a class="nounderline abstract_t">Venkatesan NN, Pine HS, Underbrink MP. Recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2012; 45:671.</a></li><li><a class="nounderline abstract_t">Gerein V, Schmandt S, Babkina N, et al. Human papilloma virus (HPV)-associated gynecological alteration in mothers of children with recurrent respiratory papillomatosis during long-term observation. Cancer Detect Prev 2007; 31:276.</a></li><li><a class="nounderline abstract_t">Xu H, Lu DW, El-Mofty SK, Wang HL. Metachronous squamous cell carcinomas evolving from independent oropharyngeal and pulmonary squamous papillomas: association with human papillomavirus 11 and lack of aberrant p53, Rb, and p16 protein expression. Hum Pathol 2004; 35:1419.</a></li><li><a class="nounderline abstract_t">Cerilli LA, Holst VA, Brandwein MS, et al. Sinonasal undifferentiated carcinoma: immunohistochemical profile and lack of EBV association. Am J Surg Pathol 2001; 25:156.</a></li><li><a class="nounderline abstract_t">Ejaz A, Wenig BM. Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis. Adv Anat Pathol 2005; 12:134.</a></li><li><a class="nounderline abstract_t">Bishop JA, Westra WH. NUT midline carcinomas of the sinonasal tract. Am J Surg Pathol 2012; 36:1216.</a></li><li><a class="nounderline abstract_t">Agaimy A, Hartmann A, Antonescu CR, et al. SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity. Am J Surg Pathol 2017; 41:458.</a></li><li><a class="nounderline abstract_t">Agaimy A, Jain D, Uddin N, et al. SMARCA4-deficient Sinonasal Carcinoma: A Series of 10 Cases Expanding the Genetic Spectrum of SWI/SNF-driven Sinonasal Malignancies. Am J Surg Pathol 2020; 44:703.</a></li><li><a class="nounderline abstract_t">Guilmette J, Sadow PM. High-Grade Sinonasal Carcinoma: Classification Through Molecular Profiling. Arch Pathol Lab Med 2019; 143:1416.</a></li><li><a class="nounderline abstract_t">Bishop JA, Andreasen S, Hang JF, et al. HPV-related Multiphenotypic Sinonasal Carcinoma: An Expanded Series of 49 Cases of the Tumor Formerly Known as HPV-related Carcinoma With Adenoid Cystic Carcinoma-like Features. Am J Surg Pathol 2017; 41:1690.</a></li><li><a class="nounderline abstract_t">Mito JK, Bishop JA, Sadow PM, et al. Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas. Am J Surg Pathol 2018; 42:1067.</a></li><li><a class="nounderline abstract_t">Luna MA. Sinonasal tubulopapillary low-grade adenocarcinoma: a specific diagnosis or just another seromucous adenocarcinoma? Adv Anat Pathol 2005; 12:109.</a></li><li><a class="nounderline abstract_t">Rooper LM, Thompson LDR, Gagan J, et al. Low-grade non-intestinal-type sinonasal adenocarcinoma: a histologically distinctive but molecularly heterogeneous entity. Mod Pathol 2022; 35:1160.</a></li><li><a class="nounderline abstract_t">Resto VA, Krane JF, Faquin WC, Lin DT. Immunohistochemical distinction of intestinal-type sinonasal adenocarcinoma from metastatic adenocarcinoma of intestinal origin. Ann Otol Rhinol Laryngol 2006; 115:59.</a></li><li><a class="nounderline abstract_t">Kennedy MT, Jordan RC, Berean KW, Perez-Ordoñez B. Expression pattern of CK7, CK20, CDX-2, and villin in intestinal-type sinonasal adenocarcinoma. J Clin Pathol 2004; 57:932.</a></li><li><a class="nounderline abstract_t">Ortiz-Rey JA, Alvarez C, San Miguel P, et al. Expression of CDX2, cytokeratins 7 and 20 in sinonasal intestinal-type adenocarcinoma. Appl Immunohistochem Mol Morphol 2005; 13:142.</a></li><li><a class="nounderline abstract_t">Sjöstedt S, Schmidt AY, Vieira FG, et al. Major driver mutations are shared between sinonasal intestinal-type adenocarcinoma and the morphologically identical colorectal adenocarcinoma. J Cancer Res Clin Oncol 2021; 147:1019.</a></li><li><a class="nounderline abstract_t">Bimbi G, Saraceno MS, Riccio S, et al. Adenocarcinoma of ethmoid sinus: an occupational disease. Acta Otorhinolaryngol Ital 2004; 24:199.</a></li><li><a class="nounderline abstract_t">Orvidas LJ, Lewis JE, Weaver AL, et al. Adenocarcinoma of the nose and paranasal sinuses: a retrospective study of diagnosis, histologic characteristics, and outcomes in 24 patients. Head Neck 2005; 27:370.</a></li><li><a class="nounderline abstract_t">Yom SS, Rashid A, Rosenthal DI, et al. Genetic analysis of sinonasal adenocarcinoma phenotypes: distinct alterations of histogenetic significance. Mod Pathol 2005; 18:315.</a></li><li class="breakAll">Faquin W, Rossi E. The Milan System for Reporting Salivary Gland Cytopathology, Baloch Z, et al (Eds), Springer, Gewerbestrasse, Switzerland 2018.</li><li><a class="nounderline abstract_t">Wasserman JK, Dickson BC, Smith A, et al. Metastasizing Pleomorphic Adenoma: Recurrent PLAG1/HMGA2 Rearrangements and Identification of a Novel HMGA2-TMTC2 Fusion. Am J Surg Pathol 2019; 43:1145.</a></li><li><a class="nounderline abstract_t">Jones AV, Craig GT, Speight PM, Franklin CD. The range and demographics of salivary gland tumours diagnosed in a UK population. Oral Oncol 2008; 44:407.</a></li><li><a class="nounderline abstract_t">Ansari MH. Salivary gland tumors in an Iranian population: a retrospective study of 130 cases. J Oral Maxillofac Surg 2007; 65:2187.</a></li><li><a class="nounderline abstract_t">Wang D, Li Y, He H, et al. Intraoral minor salivary gland tumors in a Chinese population: a retrospective study on 737 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104:94.</a></li><li><a class="nounderline abstract_t">Pires FR, Pringle GA, de Almeida OP, Chen SY. Intra-oral minor salivary gland tumors: a clinicopathological study of 546 cases. Oral Oncol 2007; 43:463.</a></li><li><a class="nounderline abstract_t">Seethala RR. Histologic grading and prognostic biomarkers in salivary gland carcinomas. Adv Anat Pathol 2011; 18:29.</a></li><li class="breakAll">World Health Organizagion (WHO) Classification of Head and Neck Tumours, El-Naggar AK, Chan JKC, Grandis JR, et al (Eds), International Agency for Research on Cancer (IARC) Press, Lyon 2017. p.160.</li><li class="breakAll">Gnepp DR, Henley J, Simpson RHW, Eveson J. Salivary and lacrimal glands. In: Diagnostic Surgical Pathology of the Head and Neck, 2nd ed, Gnepp DR (Ed), Elsevier, 2009. p.474.</li><li><a class="nounderline abstract_t">Katabi N, Ghossein R, Ali S, et al. Prognostic features in mucoepidermoid carcinoma of major salivary glands with emphasis on tumour histologic grading. Histopathology 2014; 65:793.</a></li><li><a class="nounderline abstract_t">Fehr A, Röser K, Heidorn K, et al. A new type of MAML2 fusion in mucoepidermoid carcinoma. Genes Chromosomes Cancer 2008; 47:203.</a></li><li><a class="nounderline abstract_t">Bell D, Luna MA, Weber RS, et al. CRTC1/MAML2 fusion transcript in Warthin's tumor and mucoepidermoid carcinoma: evidence for a common genetic association. Genes Chromosomes Cancer 2008; 47:309.</a></li><li><a class="nounderline abstract_t">Seethala RR, Chiosea SI. MAML2 Status in Mucoepidermoid Carcinoma Can No Longer Be Considered a Prognostic Marker. Am J Surg Pathol 2016; 40:1151.</a></li><li><a class="nounderline abstract_t">Bishop JA, Cowan ML, Shum CH, Westra WH. MAML2 Rearrangements in Variant Forms of Mucoepidermoid Carcinoma: Ancillary Diagnostic Testing for the Ciliated and Warthin-like Variants. Am J Surg Pathol 2018; 42:130.</a></li><li><a class="nounderline abstract_t">Lloyd S, Yu JB, Wilson LD, Decker RH. Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy. Am J Clin Oncol 2011; 34:76.</a></li><li><a class="nounderline abstract_t">Xu B, Drill E, Ho A, et al. Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands: A Clinicopathologic Study With Correlation Between MYB Fusion and Protein Expression. Am J Surg Pathol 2017; 41:1422.</a></li><li><a class="nounderline abstract_t">Togashi Y, Dobashi A, Sakata S, et al. MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts. Mod Pathol 2018; 31:934.</a></li><li><a class="nounderline abstract_t">Rooper LM, Lombardo KA, Oliai BR, et al. MYB RNA In Situ Hybridization Facilitates Sensitive and Specific Diagnosis of Adenoid Cystic Carcinoma Regardless of Translocation Status. Am J Surg Pathol 2021; 45:488.</a></li><li><a class="nounderline abstract_t">Otsuka K, Imanishi Y, Tada Y, et al. Clinical Outcomes and Prognostic Factors for Salivary Duct. Ann Surg Oncol 26; 23:2038.</a></li><li><a class="nounderline abstract_t">Seethala RR. Basaloid/blue salivary gland tumors. Mod Pathol 2017; 30:S84.</a></li><li><a class="nounderline abstract_t">Sebastiao APM, Xu B, Lozada JR, et al. Histologic spectrum of polymorphous adenocarcinoma of the salivary gland harbor genetic alterations affecting PRKD genes. Mod Pathol 2020; 33:65.</a></li><li><a class="nounderline abstract_t">El-Naggar AK, Callender D, Coombes MM, et al. Molecular genetic alterations in carcinoma ex-pleomorphic adenoma: a putative progression model? Genes Chromosomes Cancer 2000; 27:162.</a></li><li><a class="nounderline abstract_t">Czader M, Eberhart CG, Bhatti N, et al. Metastasizing mixed tumor of the parotid: initial presentation as a solitary kidney tumor and ultimate carcinomatous transformation at the primary site. Am J Surg Pathol 2000; 24:1159.</a></li><li><a class="nounderline abstract_t">Katabi N, Gomez D, Klimstra DS, et al. Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases. Hum Pathol 2010; 41:927.</a></li><li><a class="nounderline abstract_t">Kong M, Drill EN, Morris L, et al. Prognostic factors in myoepithelial carcinoma of salivary glands: a clinicopathologic study of 48 cases. Am J Surg Pathol 2015; 39:931.</a></li><li><a class="nounderline abstract_t">Katabi N, Ghossein R, Ho A, et al. Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. Hum Pathol 2015; 46:26.</a></li><li><a class="nounderline abstract_t">Biron VL, Lentsch EJ, Gerry DR, Bewley AF. Factors influencing survival in acinic cell carcinoma: a retrospective survival analysis of 2061 patients. Head Neck 2015; 37:870.</a></li><li><a class="nounderline abstract_t">Xu B, Wang L, Borsu L, et al. A proportion of primary squamous cell carcinomas of the parotid gland harbour high-risk human papillomavirus. Histopathology 2016; 69:921.</a></li><li><a class="nounderline abstract_t">Coutinho-Camillo CM, Brentani MM, Nagai MA. Genetic alterations in juvenile nasopharyngeal angiofibromas. Head Neck 2008; 30:390.</a></li><li><a class="nounderline abstract_t">Ponti G, Losi L, Pellacani G, et al. Wnt pathway, angiogenetic and hormonal markers in sporadic and familial adenomatous polyposis-associated juvenile nasopharyngeal angiofibromas (JNA). Appl Immunohistochem Mol Morphol 2008; 16:173.</a></li><li><a class="nounderline abstract_t">Montag AG, Tretiakova M, Richardson M. Steroid hormone receptor expression in nasopharyngeal angiofibromas. Consistent expression of estrogen receptor beta. Am J Clin Pathol 2006; 125:832.</a></li><li><a class="nounderline abstract_t">Faden DL, Algazi A. Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst 2017; 109.</a></li><li><a class="nounderline abstract_t">Brown NA, Rolland D, McHugh JB, et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res 2014; 20:5517.</a></li><li><a class="nounderline abstract_t">Kurppa KJ, Catón J, Morgan PR, et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 2014; 232:492.</a></li></ol></div><div id="topicVersionRevision">Topic 3375 Version 52.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Biopsy Interpretation of the Upper Aerodigestive Tract and Ear, Stelow EB, Mills SE (Eds), Wolters-Kluwer/Lippincott Williams &amp; Wilkins, Philadelphia 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gnepp DR. Diagnostic Surgical Pathology of the Head and Neck, 2nd ed, Saunders Elsevier, Philadelphia 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Head and Neck Pathology: A Volume in Foundations in Diagnostic Pathology Series, Goldblum JR (Ed), Elsevier Health Sciences, 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : WHO Classification of Tumours: Head and neck tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), IARC, 2022. Vol 9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747054" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The language of surgical pathology--a precis for the head and neck surgeon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1517891" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15644773" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17120195" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Critical evaluation of frozen section margins in head and neck cancer resections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17120195" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Critical evaluation of frozen section margins in head and neck cancer resections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27469263" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Determining Adequate Margins in Head and Neck Cancers: Practice and Continued Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22941934" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Surgical margins in head and neck cancer: a contemporary review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26960076" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The importance of margins in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32124417" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intraoperative Margin Assessment in Head and Neck Cancer: A Case of Misuse and Abuse?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23988568" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Early squamous cell carcinoma of the oral tongue: comparing margins obtained from the glossectomy specimen to margins from the tumor bed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26225798" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Early Oral Tongue Squamous Cell Carcinoma: Sampling of Margins From Tumor Bed and Worse Local Control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20436098" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16931119" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: an attempt to understand the sources of variation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23217539" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The binary oral dysplasia grading system: validity testing and suggested improvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26268427" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Grade of dysplasia and malignant transformation in adults with premalignant laryngeal lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17448135" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Oral premalignant lesions: is a biopsy reliable?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16316774" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term treatment outcome of oral premalignant lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32483602" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : RE: Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31803979" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Potentially malignant disorders of the oral cavity and oral dysplasia: A systematic review and meta-analysis of malignant transformation rate by subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24115154" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Proliferative verrucous leukoplakia: recognition and differentiation from conventional leukoplakia and mimics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33415517" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Proliferative Verrucous Leukoplakia: An Expert Consensus Guideline for Standardized Assessment and Reporting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25631445" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comprehensive genomic characterization of head and neck squamous cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20534998" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Human papillomavirus-associated squamous cell carcinoma of the upper aerodigestive tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36808090" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : High-risk human papillomavirus 16/18 associated with improved survival in sinonasal squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241096" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25688737" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31934915" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : HPV-positive Squamous Cell Carcinoma of the Larynx, Oral Cavity, and Hypopharynx: Clinicopathologic Characterization With Recognition of a Novel Warty Variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32415906" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prognostic significance of human papillomavirus and Epstein-Bar virus in nasopharyngeal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30116721" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Epstein-Barr Virus-Associated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19034903" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Patient and tumor factors at diagnosis in a multi-ethnic primary head and neck squamous cell carcinoma cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1757080" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The predictive value of histological classification into degrees of differentiation of squamous cell carcinoma of the larynx and hypopharynx compared with the survival of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10705095" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Surfing prognostic factors in head and neck cancer at the millennium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8595170" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30530818" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Novel prognostic histopathological grading system in oral squamous cell carcinoma based on tumour budding and cell nest size shows high interobserver and intraobserver concordance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28122134" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Tumour budding activity and cell nest size determine patient outcome in oral squamous cell carcinoma: proposal for an adjusted grading system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22529575" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A study on histological grading of oral squamous cell carcinoma and its co-relationship with regional metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30537401" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Depth of invasion as a predictor of nodal disease and survival in patients with oral tongue squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2041410" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : [Empyema and splenic abscess].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23797868" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27196434" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Association of Extracapsular Spread With Survival According to Human Papillomavirus Status in Oropharynx Squamous Cell Carcinoma and Carcinoma of Unknown Primary Site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32072378" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Regional Metastasis in Head and Neck Cutaneous Squamous Cell Carcinoma: An Update on the Significance of Extra-Nodal Extension and Soft Tissue Metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26293844" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Inter- and intra-observer variability in the classification of extracapsular extension in p16 positive oropharyngeal squamous cell carcinoma nodal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33021340" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Lymph node characteristics and their prognostic significance in oral squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26514096" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36179764" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Extent of Extranodal Extension in Oral Cavity Squamous Cell Carcinoma is Not Independently Associated With Overall or Disease-Free Survival at a 2.0-mm Threshold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32838649" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prognostic Significance of Extranodal Extension in HPV-Mediated Oropharyngeal Carcinoma: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35690646" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prognostic impact of extranodal extension (ENE) in surgically managed treatment-naive HPV-positive oropharyngeal squamous cell carcinoma with nodal metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34699271" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18088849" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Verrucous carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15785870" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Human papillomavirus in head and neck cancer: molecular biology and clinicopathological correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9570624" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Verrucous carcinoma of the larynx: a review of 53 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694517" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443616" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : National survey of head and neck verrucous carcinoma: patterns of presentation, care, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23765951" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Basaloid squamous cell carcinoma of the larynx: analysis of 145 cases with comparison to conventional squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23765951" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Basaloid squamous cell carcinoma of the larynx: analysis of 145 cases with comparison to conventional squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24418859" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Use of p40 and p63 immunohistochemistry and human papillomavirus testing as ancillary tools for the recognition of head and neck sarcomatoid carcinoma and its distinction from benign and malignant mesenchymal processes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33723761" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The Most Common Mistake in Laryngeal Pathology and How to Avoid it.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20614332" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Spindle cell lesions--neoplastic or non-neoplastic?: spindle cell carcinoma and other atypical spindle cell lesions of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493284" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical and pathologic predictors of recurrence and survival in spindle cell squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18314024" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Spindle cell carcinoma of the palatine tonsil: report of a diagnostic pitfall and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9018257" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Spindle cell carcinoma of the larynx and hypopharynx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23060353" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31509355" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Heterogeneity of p16 immunohistochemistry and increased sensitivity of RNA in situ hybridization in cytology specimens of HPV-related head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29251996" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30188786" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31679945" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34496080" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29750666" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35862863" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34375025" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19248937" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The evolution of management for inverted papilloma: an analysis of 200 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203683" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Sinonasal papillomas: A single centre experience on 137 cases with emphasis on malignant transformation and EGFR/KRAS status in "carcinoma ex papilloma".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31743131" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Transcriptionally Active HPV and Targetable EGFR Mutations in Sinonasal Inverted Papilloma: An Association Between Low-risk HPV, Condylomatous Morphology, and Cancer Risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27234382" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Activating KRAS mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25353697" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Natural History and Malignant Transformation in Recurrent Respiratory Papillomatosis: Human Papillomavirus (HPV), Dysplasia and an Autopsy Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20513045" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282764" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Recurrent respiratory papillomatosis: pathogenesis to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144058" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Recurrent respiratory papillomatosis with pulmonary involvement: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22588043" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Recurrent respiratory papillomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17935912" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Human papilloma virus (HPV)-associated gynecological alteration in mothers of children with recurrent respiratory papillomatosis during long-term observation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668901" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Metachronous squamous cell carcinomas evolving from independent oropharyngeal and pulmonary squamous papillomas: association with human papillomavirus 11 and lack of aberrant p53, Rb, and p16 protein expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11176064" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Sinonasal undifferentiated carcinoma: immunohistochemical profile and lack of EBV association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15900114" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22534723" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : NUT midline carcinomas of the sinonasal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28291122" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31934917" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : SMARCA4-deficient Sinonasal Carcinoma: A Series of 10 Cases Expanding the Genetic Spectrum of SWI/SNF-driven Sinonasal Malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779592" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : High-Grade Sinonasal Carcinoma: Classification Through Molecular Profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28877065" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : HPV-related Multiphenotypic Sinonasal Carcinoma: An Expanded Series of 49 Cases of the Tumor Formerly Known as HPV-related Carcinoma With Adenoid Cystic Carcinoma-like Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29683816" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15900111" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Sinonasal tubulopapillary low-grade adenocarcinoma: a specific diagnosis or just another seromucous adenocarcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35322195" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Low-grade non-intestinal-type sinonasal adenocarcinoma: a histologically distinctive but molecularly heterogeneous entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16466101" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Immunohistochemical distinction of intestinal-type sinonasal adenocarcinoma from metastatic adenocarcinoma of intestinal origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15333652" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Expression pattern of CK7, CK20, CDX-2, and villin in intestinal-type sinonasal adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894926" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Expression of CDX2, cytokeratins 7 and 20 in sinonasal intestinal-type adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33051725" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Major driver mutations are shared between sinonasal intestinal-type adenocarcinoma and the morphologically identical colorectal adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15688904" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Adenocarcinoma of ethmoid sinus: an occupational disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15714475" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Adenocarcinoma of the nose and paranasal sinuses: a retrospective study of diagnosis, histologic characteristics, and outcomes in 24 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492756" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Genetic analysis of sinonasal adenocarcinoma phenotypes: distinct alterations of histogenetic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492756" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Genetic analysis of sinonasal adenocarcinoma phenotypes: distinct alterations of histogenetic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31094927" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Metastasizing Pleomorphic Adenoma: Recurrent PLAG1/HMGA2 Rearrangements and Identification of a Novel HMGA2-TMTC2 Fusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17825603" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The range and demographics of salivary gland tumours diagnosed in a UK population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954313" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Salivary gland tumors in an Iranian population: a retrospective study of 130 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17577550" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Intraoral minor salivary gland tumors in a Chinese population: a retrospective study on 737 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16979373" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Intra-oral minor salivary gland tumors: a clinicopathological study of 546 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21169736" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Histologic grading and prognostic biomarkers in salivary gland carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21169736" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Histologic grading and prognostic biomarkers in salivary gland carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21169736" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Histologic grading and prognostic biomarkers in salivary gland carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25040772" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Prognostic features in mucoepidermoid carcinoma of major salivary glands with emphasis on tumour histologic grading.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18050304" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A new type of MAML2 fusion in mucoepidermoid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18181164" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : CRTC1/MAML2 fusion transcript in Warthin's tumor and mucoepidermoid carcinoma: evidence for a common genetic association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27299797" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : MAML2 Status in Mucoepidermoid Carcinoma Can No Longer Be Considered a Prognostic Marker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28877061" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : MAML2 Rearrangements in Variant Forms of Mucoepidermoid Carcinoma: Ancillary Diagnostic Testing for the Ciliated and Warthin-like Variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177363" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28719465" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands: A Clinicopathologic Study With Correlation Between MYB Fusion and Protein Expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29410490" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33165092" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : MYB RNA In Situ Hybridization Facilitates Sensitive and Specific Diagnosis of Adenoid Cystic Carcinoma Regardless of Translocation Status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Clinical Outcomes and Prognostic Factors for Salivary Duct</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28060371" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Basaloid/blue salivary gland tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31492931" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Histologic spectrum of polymorphous adenocarcinoma of the salivary gland harbor genetic alterations affecting PRKD genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10612804" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Molecular genetic alterations in carcinoma ex-pleomorphic adenoma: a putative progression model?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10935658" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Metastasizing mixed tumor of the parotid: initial presentation as a solitary kidney tumor and ultimate carcinomatous transformation at the primary site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20338616" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25970687" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Prognostic factors in myoepithelial carcinoma of salivary glands: a clinicopathologic study of 48 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439740" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24623677" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Factors influencing survival in acinic cell carcinoma: a retrospective survival analysis of 2061 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27374168" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : A proportion of primary squamous cell carcinomas of the parotid gland harbour high-risk human papillomavirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18228521" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Genetic alterations in juvenile nasopharyngeal angiofibromas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18227724" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Wnt pathway, angiogenetic and hormonal markers in sporadic and familial adenomatous polyposis-associated juvenile nasopharyngeal angiofibromas (JNA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16690481" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Steroid hormone receptor expression in nasopharyngeal angiofibromas. Consistent expression of estrogen receptor beta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27671684" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24993163" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Activating FGFR2-RAS-BRAF mutations in ameloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24374844" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : High frequency of BRAF V600E mutations in ameloblastoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
